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Section I: Chronic alcohol consumption is a leading cause of liver disease and 
liver-related death worldwide. Alcoholic liver disease includes, hepatic steatosis, 
steatohepatitis and ultimately fibrosis and cirrhosis. Emerging evidence has 
established the important role of the “gut-liver” axis in the development of 
alcoholic liver disease (ALD). Our recent work indicated that chronic alcohol 
induced perturbations in the gut microbiome and consequent changes in fatty 
acids have a major impact on the development of intestinal barrier dysfunction 
and ALD. The aim of this study was to investigate whether treatment with 
tributyrin - a butyrate prodrug results in protection against ALD in terms of 
hepatic steatosis, inflammation and injury. Tributyrin is a triglyceride that is 
rapidly absorbed and metabolized to butyrate. Moreover, it has more favorable 
pharmacokinetics compared with butyrate with low toxicity.  
In the present study, we have used a mouse model of ALD to examine the 
effects of Tributyrin oral administration on ethanol-induced changes in intestinal 
permeability and hepatic steatosis, inflammation and injury. 8–10-week old 




containing alcohol or isocaloric maltose dextrin. Tributyrin was administered to a 
sub-group of alcohol-fed animals by oral gavage (2g/kg) for 5 days/week to 
assess its effects. 
Tributyrin attenuated the ethanol-induced gut barrier dysfunction, as 
shown by the significant reduction in endotoxemia. Mechanisms of chronic 
alcohol-induced gut-barrier dysfunction were examined by immunohistochemical 
analyses of the ileum section of mice chronically fed alcohol. Specifically, alcohol 
induced a robust down-regulation of intestinal tight junction proteins ZO-1 and 
occludin which was markedly attenuated by tributyrin administration. Liver 
histological analysis showed a significant decrease in ethanol-induced hepatic 
steatosis. Tributyrin also prevented the ethanol-induced down-regulation of 
hepatic CPT-1, a key enzyme in free fatty acid β-oxidation, with a resultant 
decrease in hepatic triglycerides and free fatty acids. To further elucidate the 
mechanism by which tributyrin prevents hepatic steatosis, we performed 
experiments using primary hepatocytes. Hepatocytes were treated with alcohol 
and with/without pre-treatment with butyrate. Alcohol-induced downregulation of 
CPT-1 gene expression was significantly prevented by butyrate. Butyrate is a 
known HDAC inhibitor. Hence promoter histone acetylation state was 
investigated. In this regard, acetylation of histone 3 lysine 9 (H3K9), a critical 
feature of the active promoter state was significantly increased by butyrate and 
was essentially mediated by the p300-histone acetyltransferase. Increased 
acetylation leads to an open chromatin configuration causing increased 




promoter. Additionally RNA-Pol II binding was also increased by butyrate pre-
treatment in alcohol treated hepatocytes. These data suggest that butyrate, by 
acting as an HDAC inhibitor, induces promoter histone acetylation leading to the 
transcriptional activation of CPT-1 under pathologic conditions of alcohol 
exposure.  
Butyrate has been shown to have beneficial effects by decreasing obesity-
associated inflammation, and insulin resistance. Hence, its effects on alcohol 
induced hepatic inflammation were also investigated. F4/80 staining of liver 
sections revealed increased macrophage infiltration in 2 weeks of alcohol feeding 
whereas tributryrin administration markedly blocked macrophage infiltration. 
Tributyrin administration attenuated the ethanol mediated pro-inflammatory 
cytokine TNF-α mRNA expression. Alcohol-induced neutrophil infiltration was 
also significantly suppressed by tributyrin administration. Neutrophil infiltration 
was further confirmed by MPO activity. Tributyrin administered mice had a 
significant drop in MPO activity as compared to alcohol-fed mice at 7 weeks but 
not in 2 weeks. Inflammatory chemokine and cytokine such as CXCL-2 (MCP-1) 
and CCL-2 (MIP-2) mRNA were significantly upregulated in alcohol-fed mice and 
tributryrin administration significantly attenuated alcohol-induced induction of 
these pro-inflammatory chemokines. Notably, tributryrin also significantly 
attenuated liver injury as seen by a decrease in serum AST & ALT levels. Hence, 
the present work demonstrates that tributyrin may be useful in preventing the 
ethanol-induced pathogenic changes in the “gut-liver” axis and may prove to be a 




Section II: HIV protease inhibitors (HIV-PIs) are the major components of the 
highly active anti-retroviral therapy (HAART) and have been successfully used in 
the treatment of HIV-1 infection in the past two decades. However prolonged use 
of HAART is known to cause hepatotoxicity. Hence it is highly relevant to study 
the underlying mechanisms in HAART induced hepatotoxicity that can negatively 
impact treatment outcomes. One of the known mechanisms of hepatotoxicity 
caused due to HIV-PIs drugs is endoplasmic reticulum (ER) stress and 
subsequent activation of unfolded protein response (UPR) leading to dys-
regulation of hepatic lipid metabolism. Our recent work shows that PDE4/cAMP 
metabolism plays a significant role in alcohol-induced hepatic steatosis and 
injury. Hence in the present study, we examined the potential mechanisms 
underlying HIV-PI induced hepatic ER stress and toxicity with a particular 
emphasis on the pathogenic role of PDE4 family of enzymes.  
The effects of clinically used HIV-PIs [Ritonavir and Lopinavir] were 
examined both in a rat hepatoma cell line (H4IIE). The data obtained from these 
studies demonstrated that Ritonavir and Lopinavir in combination led to a 
significant loss of hepatocyte survival. Notably, inhibition of PDE4 by a specific 
PDE4-inhibitor, rolipram, markedly attenuated hepatotoxicity induced by PI 
treatments. Examination of the mechanistic role of PDE4 showed that PDE4 
inhibition significantly decreases the PIs-induced expression of the ER stress 
related proteins CHOP, ATF-4 and -3. Furthermore, examination of the 
PDE4/cAMP-regulated downstream signaling demonstrated the involvement of 




examined in hepatocytes treated with HIV-PI and rolipram. PKA inhibition 
significantly reversed the rolipram protective effect leading to re-expression of 
ER-stress related genes.  
 Fas/FasL signaling plays a critical role in drug-induced hepatotoxicity and 
cell death Hence activation of hepatotoxic Fas/FasL signaling in HIV-PI induced 
hepatotoxicity was investigated. Combination of Rit+Lop significantly up- 
regulated FasL and Fas expression in H4IIE rat hepatoma cell line. 
Commensurate with the increase in FasL and Fas, PDE4 expression was also 
increased with Rit+Lop treatment. Notably PDE4 inhibition down-regulated Fas 
and FasL mRNA and protein expression induced by HIV PIs whereas PKA 
inhibitor H-89 significantly reversed the rolipram effect on Fas and FasL 
expression. Taken together, these data strongly support and identify a 
pathogenic/mechanistic role for PDE4 regulated cAMP-PKA in the development 
of HIV-PI induced ER-stress and FasL mediated cell death leading to hepatic 
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DETERMINE THE EFFECT OF TRIBUTYRIN, A DIETARY 
BUTYRATE PRO-DRUG ON ALCOHOL INDUCED- 
 
A. ALTERATIONS IN GUT-LIVER AXIS & CONSEQUENT LIVER 
INJURY 
 
B. HEPATIC CHEMOKINE EXPRESSION, LEUKOCYTE 










Alcoholic Liver Disease – General Overview  
Alcohol abuse exacts a major toll on health and health costs in the United 
States. The overall costs of alcohol abuse in the United States are estimated in 
some studies to be approximately $185 billion annually. Moreover, excessive 
alcohol consumption is the third leading preventable cause of death in the United 
States. One to two million people in the U.S. are thought to have alcoholic liver 
disease (ALD) and approximately 14,000 people die of cirrhosis each year. In the 
Western world, alcohol remains the single most significant cause of liver disease, 
responsible for between 40-80 percent of cases of cirrhosis. Alcoholic hepatitis is 
an important cause of morbidity, mortality, and health care costs in the United 
States and worldwide.  
Clinically, the spectrum of ALD comprises of hepatic steatosis (fatty liver), 
steatohepatitis (hepatic inflammation) followed by fibrosis and cirrhosis 
sometimes leading to hepatocellular carcinoma. Amongst various stages of ALD, 
hepatic steatosis (fat accumulation) is an initial stage of ALD seen in >90% of the 
heavy alcohol drinkers [1]. Abstinence from alcohol can lead to significant 
reversal of lipid accumulation in the liver.  The progression from hepatic steatosis 
to steatohepatitis occurs in approximately 35% of the alcoholics. Pathologies 
such as neutrophil infiltration, kupffer cell activation, ballooning of the hepatocyte 
are indicative of alcohol-mediated steatohepatitis [2]. Sustained inflammation and 
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steatosis further lead to fibrosis and cirrhosis. Finally, 1-5% of the cirrhotic 
patients develop hepatocellular carcinoma [2]. Interestingly, only 35% of the 
heavy drinkers develop advanced stages of ALD, which indicates that other co-
factors are also involved. This includes obesity, drugs, gender, cigarette smoking 
and dietary factors [3-5]. Additionally, chronic alcohol consumption has 
synergistic effects with viruses such as Hepatitis Virus B and C as well as Human 
Immunodeficiency Virus.  
Notably, despite decades of research on understanding the pathogenesis 
of liver disease there is no FDA approved therapy available to treat any 
form/stages of ALD. Hence it is highly relevant to study the mechanisms of the 
development of ALD. This would allow investigation of the potential therapeutic 
intervention(s) to reverse/prevent ALD and forms the basis of this dissertation 
proposal.   
Alcohol-induced Hepatic Steatosis (fatty liver) and its Mechanisms  
Steatosis is the initial, most frequent hepatic manifestation that occurs in 
response to acute as well as chronic ethanol consumption. Although alcohol-
induced hepatic steatosis initially was considered to be a relatively benign state, 
it is now regarded as a significant risk factor for more progressive disease. 
Individuals with alcohol-induced hepatic steatosis are predisposed to develop 
advanced liver pathology, including alcoholic steatohepatitis (ASH), hepatic 
fibrosis, cirrhosis and even hepatocellular carcinoma. Hepatic steatosis is 
characterized by accumulation of lipid droplets (mainly triglycerides, 
phospholipids and cholesterol esters), which are formed by the esterification of 
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free fatty acids (FFA) and glycerol in the hepatocyte cytoplasm. Alcohol-induced 
hepatic lipid accumulation is caused as a result of increased de novo lipogenesis, 
decreased fatty acid oxidation and transport of lipids via very low-density 
lipoprotein (VLDL) [6].  
Alcohol and Hepatic β-oxidation 
Alcohol consumption is known to cause disturbances in the fatty oxidation 
leading to excess lipid accumulation in the liver. Oxidation of fatty acids takes 
place in different organelles namely, mitochondria and peroxisomes specific for 
β-oxidation and ω-oxidation [7, 8]. During fatty acid oxidation, lipids are targeted 
for either esterification or to mitochondrial β-oxidation. The long chain fatty acids 
are incorporated into the mitochondria and are oxidized by β-oxidation process. 
In the β-oxidation process fatty acids are transported from the cytosol to the 
mitochondrial matrix. These fatty acids are initially activated by coenzyme A in 
the cytoplasm, in the presence of fatty acyl-CoA synthetase [9]. Further, fatty 
acyl-CoA is then converted to fatty acyl carnitine by carnitine palmitoyl 
transferase (CPT-1) in the outer mitochondrial membrane. Subsequently, 
Carnitine translocase shuttles the fatty acyl carnitine across the inner 
mitochondrial membrane [9]. Finally acetyl-CoA formed in the mitochondrial 
matrix via beta-oxidation feeds into tricarboxylic acid cycle thus completing the 
oxidation to carbon dioxide and generating energy for the liver [10]. CPT-1 is the 
critical rate-limiting step in the β-oxidation pathway. Two isoforms of CPT-1 has 
been discovered [11, 12]. L-CPT-1 or liver isoform is expressed in most of the 
tissues including liver, kidney and pancreatic β cells whereas M-CPT-1 or muscle 
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isoform of CPT-1 is expressed in heart, skeletal muscle and adipose tissue [12, 
13].  
Under normal conditions, CPT-1 controls approximately 80% of β-
oxidation process in the liver and hence decrease in its expression is a crucial 
event in the hepatic fat accumulation [14]. Indeed, it has been shown that 
normalization of CPT-1 expression alone is sufficient to increase fatty acid 
oxidation and attenuate hepatic steatosis [15]. Specifically, these studies showed 
that a moderate increase in CPT-1 expression and activity is able to substantially 
reduce the hepatic TG burden on either a standard or high-fat diet.  
Under pathologic conditions of both chronic and binge alcohol 
consumption, CPT-1 expression is significantly down regulated leading to hepatic 
steatosis [16, 17]. Importantly, increase in CPT-1 expression by resveratrol and 
zinc have shown to prevent chronic ethanol mediated effects [18, 19]. 
Additionally, our binge alcohol feeding model has documented that prevention of 
ethanol induced decrease in CPT-1 expression markedly attenuates hepatic 
triglyceride accumulation, steatosis, and injury [17]. 
Peroxisomal β-oxidation 
Peroxisomes are ubiquitous organelles having important metabolic 
functions such as β-oxidation of very long-chain α and β fatty acids (VLCFA), α-
and β-oxidization of long branched chain fatty acids, synthesis of cholesterol and 
ether lipids[20-22].  Mechanistically, peroxisomal biogenesis occurs via de novo 
synthesis from the endoplasmic reticulum (ER) or via increase in number through 
growth and division [23-25]. Pharmacoloigcal agents such as fenofibrate, a 
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peroxisome proliferator-activated receptor-α agonist and SCFA butyrate were 
shown to alleviate fatty liver by increasing the peroxisomal abundance. Although 
in a NAFLD mice model it has been shown that peroxisomal b-oxidation is 
critically involved in lipid accumulation and contributes to fatty liver disease [26], 
similar studies are lacking in ALD.  
 
Regulation of CPT-1 gene expression and function: Relevance to alcohol- 
induced hepatic steatosis  
Role of Peroxisome proliferator-activated receptor-alpha (PPAR-α)  
PPAR-α	is a nuclear hormone receptor which is abundantly expressed in 
the tissues such as liver and muscle that have high capacity for fatty acid 
oxidation such as liver and muscle [27]. Long chain fatty acids are ligands of 
PPAR-α. Upon ligand binding PPAR-α dimerizes with retinoid X receptors (RXR) 
at the PPAR response element (PPRE) site in the first intron of the CPT-1 gene 
[28]. Emerging evidence has shown that fibrates or other PPAR-α agonists can 
attenuate diet-induced fatty liver [29]. Several genes involved in transport and 
release of free fatty acids as well as in mitochondrial and peroxisomal fatty acid 
β-oxidation pathways [30]  including CPT-1 are regulated by PPAR-α [31-33]. 
However, CPT-1 can also be regulated in a PPAR-α independent manner [34, 
35]. 
Alcohol metabolism both in vivo and in vitro inhibits PPAR-α activation 
[36].	Previous studies by Fischer et al. [37] have shown that mice chronically fed 
alcohol decrease RXR-α protein levels reducing DNA binding of the PPAR-
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α/RXRα heterodimer. This led to a decrease in PPAR-α regulated genes in the 
liver resulting in the development of fatty liver. Further, in these studies, a potent 
PPAR-α agonist - WY14,643 was observed to prevent the accumulation of 
hepatic fat in the alcohol-fed mice by increasing the PPAR-α expression as well 
as by increasing the ability of PPAR-α/RXR-α heterodimer complex to bind to the 
consensus DNA response element (PPRE). Similarly, Nanji et al [38] also 
showed that intragastric ethanol infusion causes down-regulation of PPAR-α 
activity leading to fatty liver, which was reversed by clofibrate, a PPAR-α agonist.  
These studies document the role of PPAR-α in the development of alcohol 
induced fatty liver. 
Role of transcriptional factors HNF4α, CREB, Sp-1  
 Hepatocyte nuclear factor 4α (HNF4α) plays a critical role in the 
maintenance of hepatocyte phenotype as well as in the regulation of several 
metabolic genes involved in gluconeogenesis, bile acids synthesis, conjugation 
and transport. HNF4α acts as a significant transcription factor in the regulation of 
CPT-1 gene expression. Liver specific knockout of HNF4α  develop 
hepatomegaly and accumulation of glycogen and lipids [39, 40]. Moreover, 
Talianidis et al., has shown that liver specific HNF4α knockout mice had 50% 
reduction in the CPT-1 expression[41].  In this study, recruitment of PPAR-α on 
CPT-1 promoter was independent of HNF4α. However the lack of induction of 
CPT-1 gene expression in HNF4a KO suggests that co-operation between 
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activated PPAR-α and HNF4α is essential for proper regulation of CPT-1 gene 
expression [41]. 
CREB has also been demonstrated to be a transcription factor that 
participates in the activation of CPT-1 gene expression [42]. CREB has been 
shown to bind the CPT-1 promoter region at a cAMP-responsive unit (CRU) and 
is comprised of two cis-acting elements - a DR1 motif and a CRE-like element 
(TGACG). Importantly, it has been demonstrated that both CREB and HNF4α 
bind to the CPT-1-I promoter. Binding of both CREB and HNF4α is essential for 
cAMP responsive CPT-1 gene expression [42]. These data also suggest that 
besides PPARα, HNF4α can also cooperate with CREB during the transcriptional 
activation of CPT-1 gene expression. However the effect of alcohol on HNF4-α 
and CREB mediated transcriptional regulation of CPT-1 remains largely 
undetermined.   
 It has been shown that the transcription factors Sp1, Sp3 and nuclear 
factor Y (NF-Y) bind to sites in the CPT-1 proximal promoter and participate in 
the developmental and hormonal control of CPT-1 transcriptional regulation as 
well as basal gene expression [43]. A recent study showed that plant flavonoids 
ingredients such as Ginkgo biloba extract up-regulate CPT-1 through increased 







Role of Co-activators and Co-repressor  
Peroxisome proliferator-activated receptor-γ  coactivator (PGC-1) 
Peroxisome proliferator-activated receptor-γ co-activator (PGC-1) act as a 
co-activator for several fatty acid oxidation genes, and particularly plays a critical 
role in the transcriptional activation [35]. The role of PGC-1 as a critical regulator 
of CPT-1 gene expression is clearly documented by the findings that show that 
overexpression of PGC-1 alone is sufficient to induce CPT-1 transcription [45]. 
Co-activator function of PGC-1 is activated via its deacetylation which is effected 
by the atypical HDAC – Sirtuin 1 (Sirt1) [46, 47]. Functionally, activated PGC-1 
interacts/binds and co-activates nuclear receptor transcription factor PPAR-α as 
well as non-nuclear transcription factor HNF4α during the transcriptional 
activation of the CPT-1 gene [41]. As a co-activator, upon binding the respective 
transcription factors, PGC-1 binds and recruits histone acetyltransferase (HAT) 
proteins including CREB-binding protein/p300 and steroid receptor coactivator-1 
(SRC-1). Recruitment of HATs by PGC-1 increases promoter histone acetylation 
and remodeling of the chromatin that is transcriptionally permissive leading to 
CPT-1 gene transcription [48]  
With regards to alcohol consumption Leiber’s group has shown that PGC-
1 mRNA and protein expression were significantly down regulated during chronic 
alcohol feeding [49]. These data support the notion that alcohol-induced 
decrease in PGC-1 expression is a major pathogenic mechanism that contributes 




Role of Epigenetic Mechanisms in the Regulation of CPT-1 gene expression  
Promoter histone acetylation  
Gene expression is dynamically regulated by chromatin modifications on 
histone tails, and histone acetylation promotes transcription, whereas histone 
deacetylation negatively regulates transcription. Steady-state levels of acetylation 
result from the balance between the opposing activities of histone 
acetyltransferases (HATs) and HDACs. Transcriptional activation of CPT-1 has 
been demonstrated to be influenced by both HATs as well as HDACs [17].   
HATs - particularly, CBP/p300 and SRC-1 can be recruited to the CPT-1 gene by 
PGC-1 co-activator that increases promoter histone acetylation and 
transcriptional activation [50] In contrast, HDACs - particularly HDAC3 can also 
be recruited to the CPT-1 promoter by the co-repressor N-CoR that decreases 
promoter histone acetylation and transcriptional activation [50].  Work done by 
our group has demonstrated that increase in HDAC3 expression and consequent 
N-CoR-HDAC3 mediated down-regulation of CPT-1 expression is the key 
epigenetic mechanism that underlies binge alcohol induced hepatic steatosis and 
injury [17]. Moreover, the data obtained from this work also demonstrated that by 
targeting HDAC3 activity, the binge alcohol-induced decrease in CPT-1 can be 
prevented and hepatic steatosis markedly attenuated [17]. Importantly, these 
data also strongly implicated that targeting HDAC activity represents a potential 






Role of Lipogenesis in Alcohol-induced hepatic steatosis 
Sterol regulatory element-binding proteins (SREBPs) 
Another mechanism that underlies the development of hepatic steatosis is 
lipogenesis. Majority of the enzymes and proteins involved in lipogenesis caused 
by alcohol are regulated by SREBPs. When activated, SPREBPs that are bound 
to the endoplasmic reticulum are released into the nucleus. SREBPs plays a 
critical role in regulating the synthesis of cholesterol, fatty acids and triglycerides 
in liver by modulating the activation of more than 30 genes in the liver including 
fatty acid synthase, ACC, stearoyl-CoA desaturase, ATP citrate lyase, and malic 
enzyme. Several	studies have shown the involvement of SREBP-1 in the 
progression of fat accumulation using in vivo as well as in vitro systems. [51] 
During alcohol feeding increased levels of SREBP-1 protein and mRNA was 
observed in alcohol-fed mice [52]. Metabolism of alcohol to acetaldehyde 
increases the formation of mature SREBP-1 protein enhancing fat production 
(hepatic lipogenesis) leading to fatty liver.  
Mammalian sirtuin-1 (SIRT-1) 
SIRT1, a NAD+ - dependent class III histone deacetylase protein is a 
metabolic master regulator. SIRT-1 plays an important role in regulating lipid 
metabolism and inflammation by targeting the acetylation status of various 
targets such as histones, transcriptional regulators and their co-activators [53-
55]. Alcohol consumption down-regulates SIRT-1 in hepatic cells and tissues 
leading to excess fat accumulation and inflammatory responses which 
progresses to alcoholic fatty liver disease (AFLD) [49, 56-58]. SIRT-1 has been 
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shown to bind to Sterol regulatory element-binding proteins (SPREBP-1) 
resulting in its inactivation via deacetylation.  Alcohol consumption reduces the 
level of SIRT-1 resulting in the higher levels of acetylated nuclear form of 
SREBP-1c causing increased fat production in the liver. Acute and chronic 
alcohol consumption increases the expression of several SREBP-1 regulated 
fatty acid biogenesis related enzymes leading to excess hepatic lipid 
accumulation. Importantly, SREBP-1 KO mice were significantly protected from 
AFLD [59]. SIRT1 also de-acetylates PGC-1 in at least 13 lysines at different 
domains of the protein[60]. SIRT1 directly interacts with and maintains PGC-1 in 
the deacetylated active form bound to the chromatin thus increasing the rate of 
transcription of CPT-1 [46, 47]. This indicates that PGC-1 could undergo cycles 
of acetylation and deacetylation that are SIRT1 activity dependent [60]. 
Additionally, SIRT-1 positively regulates PPAR-α. As mentioned before, PGC-1 
co-activates with PPAR-α to induce mitochondrial fatty acid oxidation enzymes. 
Hence disruptions in the regulation of PPAR-α and PGC-1 due to down-
regulation of SIRT-1 have been implicated in the development of AFLD in 
animals [61-64]. 
Alcohol-induced hepatic inflammation and injury and its Mechanisms 
 
A major factor responsible for the development of alcoholic liver disease is 
immune dysregulation and increased production of pro-inflammatory 
cytokines/chemokines which leads to chronic hepatic inflammation.  Liver 
inflammation is associated with hepatomegaly as well as increased infiltration of 
granulocytes, monocytes and lymphocytes. 
	13	
	
Role of kupffer cell activation by LPS in alcohol-induced liver inflammation 
and injury 
Several reports have shown that chronic alcohol abuse leads to an 
increase in gram-negative bacteria in the intestine. Additionally, alcohol is known 
to disrupt the gut barrier function by decreasing tight junction protein expression 
in the intestine and causing endotoxemia by lipopolysaccharide (LPS) release in 
the systemic circulation [65, 66].  Endotoxin is recognized by hepatic 
macrophages (kupffer cells) in the portal circulation and is removed from the 
systemic circulation. In the liver, exposure of LPS to kupffer cells results in 
kupffer cell activation leading to the production of inflammatory cytokines such as 
TNF-α and reactive oxygen species (ROS). These inflammatory cytokines and 
ROS further activate other liver cells such as hepatocytes, stellate cells and 
endothelial cells and enhance LPS induced liver damage[67]. Our lab and 
several studies have shown that LPS inducible TNF-α production is increased in 
chronic alcoholics and in alcohol-fed animals [68, 69]. Role of TNF-α in alcoholic 
liver disease is further documented by McClain et al. where elevated serum 
levels of TNF-α inducible cytokines and chemokines including IL-6, IL-8 and IL-
18 were reported in alcoholic hepatitis (AH) patients [70]. Notably, alcohol 
administration to TNF-α knockout mice did not develop liver injury [71], 





Role of Toll-Like receptors (TLRs) in alcohol-induced hepatic inflammation 
and injury 
TLRs are pattern recognizing receptors that sense pathogen-derived 
molecules as well as host-derived danger signals [72, 73]. TLRs are widely 
expressed on hepatocytes as well as kupffer cells. Out of 10 different TLRs, 
TLR4 is known to be highly relevant in ALD and is widely studied. LPS binds to 
TLR4 and activates the production of inflammatory cytokines suggesting that 
TLRs play a critical role in the pathophysiology of various liver disease [74]. 
LPS/TLR4 signaling pathway activates transcription factors such as NF-kB that 
induces pro-inflammatory cytokines such as IL-6, IL-8 and TNF-α leading to liver 
injury [75, 76]. Exposure to LPS during alcohol consumption results in up-
regulation of TLR-4 expression on the Kupffer cells as well as other cell types in 
the liver. This LPS/TLR4 signaling plays an important role in the pathogenesis of 
ALD [77].   
Role of Monocyte Chemoattractant Protein-1 (MCP-1) and adhesion 
molecules in alcohol-induced hepatic inflammation and injury 
In addition to the role of TLR4/LPS signaling pathway and TNF-
production, chemokines and adhesion molecules are also equally responsible   
for the development of chronic alcohol induced liver injury [78, 79]. Neutrophil 
infiltration and monocytes recruitment in the liver is associated with chronic-
alcohol induced liver injury.  Chemokine such as CCL2 also referred to as 
monocyte chemotactic peptide-1 (MCP-1), is a member of the C-C chemokine 
family. It is expressed in most of the liver cell types such as hepatocytes, stellate 
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cells and kupffer cells [80, 81] and is a potent chemotactic as well as 
chemoattractant for monocytes [82, 83]. Previous studies have shown that CCL2 
mRNA and protein expression is up regulated in chronic alcohol feeding in 
rodents as well as in alcoholic hepatitis patients [80, 84-88]. Increased levels of 
CCL2 recruited and activated monocytes /macrophages to the damaged tissue 
site and stimulated pro-inflammatory cytokines production such as TNF-α, IL-1β 
and IL-6 [89, 90]. Apart from activating macrophages, CCL2 plays a major role in 
the development of hepatic steatosis and liver injury. Studies in primary 
hepatocytes have demonstrated that CCL2 induces lipid accumulation during 
tissue injury [91]. Moreover, a transgenic mouse overexpressing CCL2 in 
adipose tissue showed increased hepatic triglycerides levels [92]. Interestingly, 
CCL2 knockout mice were protected against alcoholic liver injury by the induction 
of genes responsible for fatty acid oxidation and inhibition of pro-inflammatory 
cytokines [93]. Since CCL2 regulates macrophage activation, pro-inflammatory 
responses and hepatic steatosis in a chronic alcohol mice model, 
pharmacological approaches to block CCL2 would be beneficial in treating early 
stages of alcoholic liver disease such as steatohepatitis. 
Intercellular adhesion molecule (ICAM-1) is expressed on kupffer cells, 
hepatocyte and endothelial cells. ICAM-1 recruits leukocytes into inflammatory 
sites by binding to its ligands LFA-1 or Mac-1, which are members of the 
leukocyte integrin family. The activated leukocytes injure tissue by releasing 
oxidants and proteases. Thus ICAM-1 could be involved in the pathogenesis of 
inflammatory liver diseases such as ALD. ICAM-1 is associated with chronic 
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alcohol exposure in patients with alcoholic liver disease [79]. Previous studies 
done by Kono group have shown that ICAM-1 knockout mice were protected 
from chronic ethanol induced liver injury by decreasing neutrophil infiltration and 
hepatic steatosis [78]. Hence ICAM-1 plays a critical role in the recruitment of 





Gut-Liver Axis in Alcoholic Liver Disease 
Alcohol and gut barrier function 
There is increasing evidence that demonstrates a critical pathogenic role 
for the gut-liver axis in the development of ALD [94]. Alcohol has been shown to 
change the composition of the microbiome as well as impair intestinal integrity 
and barrier function [94, 95]. Integrity of intestinal barrier function is regulated, in 
part, by the epithelial tight junction (TJ) complex composed of proteins such as 
zonula occludens (ZO), occludin and claudins [96, 97]. The TJ complex 
establishes intestinal barrier integrity by connecting the inter-epithelial cell 
spaces and inhibiting the paracellular passage of microbes and microbial 
products and other luminal contents [98-100]. An intact intestinal epithelial barrier 
plays a major role in preventing intestinal invasion of luminal pathogens and 
antigenic molecules and their subsequent migration to the liver and potentially 
the systemic immune system.  Accordingly, portal and systemic bacterial derived 
lipopolysaccharide (LPS) levels are nearly undetectable in normal rats as well as 
healthy people [76, 101, 102]. The clinical relevance of intestinal barrier 
dysfunction has been recognized by its pathogenic association with the 
development of ALD [103]. Direct evidence for decreased gut barrier function and 
increased intestinal permeability was provided by the observations that oral 
administration of LPS to alcohol-fed rats significantly increased systemic 





Gut-derived endotoxemia and alcohol-induced liver injury 
Besides the disruption of the gut barrier function, alcohol induced 
alterations in the gut microbiota (dysbiosis) also can cause increased intestinal 
endotoxin production, enhanced metabolism of ethanol into acetaldehyde leading 
to further increase in intestinal permeability and translocation of bacteria and 
bacterial products [105-112]. Recently our group had performed metagenomic 
analyses to examine the effects of chronic alcohol feeding on the gut bacterial 
microbiome by employing deep 16s rRNA gene sequencing using DNA isolated 
from fecal samples [109]. The findings from this study showed that alcohol 
feeding leads to significant shifts in the gut bacterial community with a marked 
increase in the phylum Proteobacteria comprised of gram negative bacteria that 
contain LPS in their cell wall and are the principal source of intestinal endotoxin 
and systemic endotoxemia. Importantly, ethanol-mediated endotoxemia, along 
with hepatic steatosis, inflammation and injury were markedly attenuated by 
treatment with a probiotic Lactobacillus rhamnosus GG (LGG). 
 Due to its anatomical links to the gut, the liver is constantly exposed to 
gut-derived bacterial products, and functions as a major filter organ and a first 
line of defense. The frequency of systemic endotoxemia has been observed to 
be significantly greater in patients with alcoholic cirrhosis than in non-alcoholic 
cirrhotic subjects [76, 113]. Notably, plasma endotoxin levels are also 
significantly elevated in alcohol consuming subjects without evidence of liver 
disease [113]. These findings suggest a direct role for alcohol in inducing 
systemic endotoxemia. Gut-derived endotoxin is a crucial mediator of liver injury 
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and hepatic fibrosis/cirrhosis [114-116]. Importantly, gut-derived endotoxin, 
seems to play a major role in the pathogenesis of ALD, as demonstrated by the 
reduction of alcoholic liver injury following elimination of the Gram-negative 
microbiota by antibiotics [117] and the sensitization to LPS-induced liver injury 
following long-term ethanol exposure [118, 119]. 
Role of short chain fatty acids (SCFA) specifically butyrate in intestinal 
health and diseases 
The human gut harbors large and dynamic bacterial community consisting 
of 300-500 different species of bacteria and the number of microbial cells within 
the gut is 10 times larger than the eukaryotic cells in the human body [120, 121].  
Short chain fatty acids are the processed by-products of the undigested long 
chain polysaccharide by anaerobic bacteria present in the gut. The short chain 
fatty acids found in the intestinal lumen includes acetate, propionate and butyrate 
[122, 123] in the constant molar ratio of 60:25:15. Although butyrate is the least 
abundant SCFA, it is important in maintaining the colonic mucosal health and 
also serves as a main energy source for colonocytes [124]. In the colon gram-
positive anaerobic bacteria produce butyrate. Specifically, two groups of 
butyrate-producing bacteria are Faecalibacterium prausnitzii. belonging to the 
Clostridium leptum cluster, and Eubacterium rectale/Roseburiaspp. belonging to 
the Clostridium coccoides cluster of firmicute bacteria [125]. During the 
fermentation process decrease in the luminal pH is conducive for the growth of 
butyrate-producing bacteria [126]. Previous studies from our lab have shown that 
chronic alcohol administration alters the intestinal microbial environment by 
increasing luminal pH leading to hepatic steatosis and inflammation and injury 
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[109]. This could possibly explain the butyrate depletion in chronic alcohol 
consumption. 
Butyrate enters the cell by non-ionic diffusion, SCFA/HCO-3 exchange, and 
active transport by SCFA transporters.  Studies have shown that butyrate 
exhibits a protective role by acting as a HDAC inhibitor [127]. Butyrate inhibits 
majority of the HDACs except class II HDAC-6 and -10 and class III [127].   In 
colon carcinoma cells, butyrate causes an imbalance in the histone acetylation 
state affecting transcription of genes involved in cell cycle differentiation and 
apoptosis and progression of cancer.[127-131]. Additionally, butyrate has been 
shown to inhibit inflammatory responses through NFκB inhibition [132-134]. 
Butyrate also has a potential application in treating and preventing molecular 
syndromes such as diet induced obesity and insulin resistance in humans [135]. 
Overall butyrate has a wide spectrum therapeutic potential in treating many 
disease state as well as maintaining intestinal homeostasis by different 
mechanisms the most common being butyrate acting as an HDAC inhibitor.  
Limitations of Butyrate therapy 
Although previous literature data has shown that butyrate has wide 
spectrum possibilities as a therapeutic potential there are certain limitation to its 
administration. Parental administration of butyrate has a very short plasma half-
life due to which a sustained infusion of butyrate via i.v dosing is needed to 
maintain the therapeutic concentration of butyrate in the plasma [136-139]. High 
doses of i.v. butyrate solution can cause hypernatremia with narrow safety 
window [140].  
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Tributyrin as a best alternative for butyrate administration 
Tributyrin (a prodrug of butyrate) is a triglyceride containing three butyrate 
moieties esterified to glycerol. It is found in variety of foodstuff such as dairy 
products [141]. Tributryin has better pharmacokinetic and pharmacodynamics 
properties as compared to butyrate. The half-life of tributyrin is 40mins and it is 
well tolerated when compared to i.v. butyrate solution [140, 142]. Oral 
administration of Tributryin exhibits direct effects on liver by increasing the 
hepato-portal concentration of butyrate [142, 143]. Recent research by Miyoshi  
has shown that oral administration of tributyrin, upon digestion in the upper GI 
tract, increases the butyrate concentration in the hepato-portal circulation and 
attenuates LPS-induced liver injury and inflammatory reactions via suppression 







We hypothesized that oral administration of tributyrin significantly attenuates 













MATERIALS AND METHODS 
Animal Model 
Eight-week-old male C57BL/6N mice were obtained from Harlan (Indianapolis, 
IN). All mice were housed in a pathogen-free, temperature-controlled animal 
facility accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care with 12 hour light/12 hour dark cycles. All experiments 
were carried out according to the criteria outlined in the Guide for Care and Use 
of Laboratory Animals and with approval of the University of Louisville Animal 
Care and Use Committee. Animals were fed a modified Lieber-DeCarli liquid diet 
containing alcohol (35% of total calories) and enriched in unsaturated fat (corn 
oil) Research Diet, New Brunswick, NJ. Control liquid maltose-dextrin diets 
provided 40% of energy from fat, 43% - from carbohydrate, 17% - from protein. 
Initially, all mice were given the control liquid maltose dextrin diets ad libitum for 
one week. Afterwards, mice were fed either the liquid ethanol diet or the control 
liquid maltose-dextrin diet. Ethanol was gradually increased every 3-4 days from 
11.2% to 35% of total calories (5.0% [vol/vol]). The mice were fed with the 
alcohol diet (5% alcohol vol/vol) ad libitum. The control mice were pair-fed with 
maltose-dextrin diets on an isocaloric basis. Tributyrin (Tb) purchased from 
Sigma Aldrich (St. Louis MO) was orally gavaged at 2g/kg 5 days a week in 





Tributyrin was purchased from Sigma (St. Louis MO) 
Liver Histopathological Examination 
For histological analysis, liver sections were fixed in 10% buffered formalin for 24 
hours and embedded in paraffin. Tissue sections were stained with hematoxylin-
eosin (H&E) and examined under light microscopy at 40× magnification. 
Oil-Red-O Staining 
To examine the amount of fat accumulation, the liver sections were stained with 
Oil-Red-O. Frozen liver sections were washed in phosphate buffered saline twice 
for 5 minutes. Oil-Red-O and 85% propylene glycol were added with agitation for 
15 minutes, followed by washing in tap water. 
Immunohistochemical staining 
Mice liver sections were stained with F4/80+, and CAE staining, and tight-
junction proteins such as anti-ZO-1 and Claudin antibody. Commercially 
available antibody against and CPT-1 (Proteintech Group Inc., Chicago, IL) was 
used for CPT-1 analysis. Assays were performed according to the 
manufacturers’ protocols. 
 RNA Isolation and Real-Time PCR Analysis 
Total RNA was isolated from the liver tissues using TRlzol®, according to 
manufacturer's instructions. For real time PCR, the first strand cDNA was 
synthesized using qScriptTM cDNA SuperMix (QuantaBiosciences, Inc, 
Gaithersburg, MD) using 400ng of the total RNA. The RT conditions were 10 
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mins at 25°C, 30mins at 48°C and 5 mins at 85°C. Real time PCR was performed 
with an ABI prism 7500 sequence detection system and PerfeCtaTM SYBR 
Green FastMixTM, Low ROX reagent (Quanta Biosciences, Inc.).Each sample 
was run in duplicate reactions. Reverse transcriptase polymerase chain reaction 
(RT-PCR) assays were used to assess mRNA levels of desired genes liver 
tissues and in primary hepatocytes. The primers amplifying the genes examined 
were designed in the lab and obtained from Intergrated DNA Technologies, Inc 
(Coralville, IA). The parameter threshold cycle (Ct) was defined as the fraction 
cycle number at which the fluorescence passed the threshold. The relative gene 
expression was analyzed using the 2-AACt method by normalizing with β-actin 
mRNA gene expression in all the experiments and is presented as fold change 
over Untreated which is set at 1. 
Assessment of Liver injury 
Kits for biochemical analysis were purchased from the following: alanine 
aminotransferase (ALT), Aspartate Aminotransferase (AST) and triacylglycerols 
(TAG), Thermo Electron (Melbourne, Australia); nonesterified-fatty acid (NEFA), 
Wako Chemical USA (Richmond, VA, USA). For liver TAG assay, hepatic tissue 
(100 mg) was homogenized in 50 mM NaCl. The homogenate (500 µl) was 
mixed with chloroform/methanol (2:1, 4 ml) and incubated overnight at room 
temperature with gentle shaking. Homogenates were vortexed and centrifuged 
for 5 min at 3000×g. The lower lipid phase was collected and concentrated by 
vacuum. The lipid pellets were dissolved in 1% Triton X100 in phosphate-
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buffered saline, and hepatic TAG content was determined via enzymatic 
colorimetric methods.  
Blood Endotoxin Assay 
Plasma endotoxin levels were measured with Limulus Amebocyte Lysate kit 
(Lonza, Walkerville, MD) according to manufacturer’s instructions.   
MPO activity assay 
For hepatic myeloperoxidase activity (MPO), liver samples were homogenized 
(10ug/200ul) in 200mM Nacl, 5mM EDTA, 10mM tris, 10% glycerin and 
centrifuge at 1500g for 15mins. Activity was measured according to 
manufacturer’s instuctions (Hycult Biotech Plymouth Meeting, PA) at 450nm 
using a plate reader. Results are expressed as mg of MPO activity/ gram of 
protein, as determined by Lowry Protein assay (Bio-Rad Hercules, CA)   
Invitro studies 
Rat primary hepatocytes were used in this study. Hepatocytes were isolated from 
sprague dawley rats. Hepatocytes were treated with alcohol (50mM) with/without 
NaB (2mM) which was pre-treated for half hour.  At the end of 48hours, alcohol 
and/or butyrate treated cells were treated with/without TNF-α (20ng/ml).  
RAW 267.4 macrophages were also used in this study. They were treated with 
LPS (10ng/ml) for 4 hours and pre-treated with/without NaB 2mM and 
Triochostain A (TSA) (100ng/ml) for half hour. All cells were cultured in 
Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 10 U/ml penicillin, and 10~g/ml streptomycin. Cells were 
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maintained in an incubator at 37°C with humidified 5% CO2. Cells were plated 
and incubated overnight before treatment, in all experiments. 
Chromatin Immunoprecipitation (ChIP) and qChIP PCR analysis 
The ChIP assay was conducted using the ChIP assay protocol established in the 
lab. Briefly, 10 X 106 cells were crosslinked with 1% formaldehyde- 1 X-glycine 
and lysed in lysis buffer containing protease inhibitor cocktail.  Enzymatic 
digestion of DNA was performed to produce chromatin fragments of 100–166 bp, 
which were confirmed by running the chromatin on a 1% agarose gel. ChIP 
antibodies directed against protein of choice were used for immunoprecipitation. 
Anti-acetyl H3K9, anti-p300, anti-PGC-1, anti-Sp-1 and anti-RNA Polymerase II 
were from EMDMillipore (MA, USA). The lysates were incubated overnight with 
antibody, following which the antibody/protein complexes were 
immunoprecipated using magnetic beads. Successive washes were performed 
with low salt, high salt, LiCl and Tris EDTA (TE) wash buffers. After reverse 
crosslinking and purification, pure DNA was eluted in elution buffer (1% SDS, 0.1 
M NaHCO3). qChIP-PCR was performed using the ABI Prism 7500 Sequence 
Detection System. ChIP- PCR primers designed for the regions of the CPT-1 and 
PGC-1 promoters were used and their sequences are as follows: 
Data was analyzed as Differential Occupancy Fold Change. ChIP-qPCR results 
were calculated  by ΔΔCt method (since all Ct values for a binding site are 
determined from the same qPCR assay) where each ChIP DNA fractions Ct 
value was normalized to the  Input DNA fraction  Ct value using ΔCt [normalized 
ChIP] = (Ct [ChIP] - (Ct [Input] ). The difference between the normalized 
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experimental sample (S2) and the control sample (S1) ChIP fraction Ct values 
(second ΔΔCt) was determined using ΔΔCt [S2-S1] = ΔCt [S2: normalized ChIP] 




mRNA PCR primer sequences  
 
Rat   
r.n_CPT-1a_F2 CTGCATGGAAGATGCTTTGA 
r.n_CPT-1a_R2 GCCATGACATACTCCCACAA 
    
r.n._Ccl2_F2 GTCTCAGCCAGATGCAGTT 
r.n._Ccl2_R2 CTCTTGAGCTTGGTGACAAAT 
    
Mouse   
mm_CPT-1a_F1 GCTGCACTCCTGGAAGAAGA 
mm_CPT-1a_R1 GGAGGGGTCCACTTTGGTAT 
    
mmCcl2_F GGCTCAGCCAGATGCAGT 
mmCcl2_R TGAGCTTGGTGACAAAAACTACAG 
    
mmCxcl2_F3 GCGCCCAGACAGAAGTCATA 
mmCxcl2_R3 TCCAGGTCAGTTAGCCTTGC 
    
mm_Icam1_F2 CGCTGTGCTTTGAGAACTGT 
mm_Icam1_R2 TGAGGTCCTTGCCTACTTGC 
    
m_Actb_F2 CAGCTGAGAGGGAAATCGTG 
m_Actb_R2 CTCCAGGGAGGAAGAGGATG 










ChIP PCR Primers 
CPT-1 TRE For GGTGACGTTGGCTGAGCAA 
CPT-1 TRE Rev TGAGCCCCTGTACACGTTTTG 
    
r.n.CPT-1_Chp2_F ATGGGCATGGCTTTAATGAG 
r.n.CPT-1_Chp2_R GGCTAGGACCCGAGCTTGT 
    
    
r_n_CPT-1GCTSs_F4 AGCCTCGCCCGCCCCTGCTC 
r_n_CPT-1_GCTSs_R4 CAGCGCTGCCCTCCCGGTGTC 
    





Data are presented as means± SD for the indicated number of independently 
performed experiments. Student's t-test and one-way ANOVA with Bonferroni 
multiple comparison test were used for the determination of statistical 















Tributyrin protects alcohol mediated down-regulation of tight-junction 
proteins and resultant intestinal permeability and systemic endotoxemia  
Intestinal tight junctions (TJ) play a major role in maintaining the barrier integrity, 
thus preventing release of toxins such as endotoxin into the systemic circulation.  
ZO-1 and Occludin are tight junction proteins, critical for the gut integrity and 
barrier function. Initially we investigated the effect of tributyrin on TJ proteins in 
chronic alcohol fed animals. Mice were orally administered tributyrin at a 
concentration of 2g/kg with or without 5% Alcohol via Lieber DeCarli diet for 4 
weeks. The expression of TJ proteins specifically ZO-1 and Occludin was 
examined by immunostaining the intestinal ileum sections (Fig. 2). Similar to 
other studies, we also observed that chronic alcohol administration decreased 
ZO-1 and Occludin protein expression in the ileum compared to pair-fed mice. 
Notably, tributyrin administration prevented the chronic alcohol-induced loss of 
ZO-1 and occludin proteins. Tributyrin alone group showed no change in 
expression of these proteins.  This data showed that tributyrin administration can 
restore the barrier integrity by preventing the alcohol-induced decrease in tight 
junction proteins. Hence, we next examined the effect of tributyrin on barrier 
function/permeability by measuring the systemic endotoxin levels. The data 
showed that chronic alcohol consumption caused increase in systemic endotoxin 
levels.  Importantly, tributyrin treatment significantly attenuated alcohol-induced 
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increase in serum endotoxin levels (Fig.3). Overall, these data showed that 
tributyrin protects the gut barrier function by restoring tight-junction proteins and 
resultant decrease in intestinal permeability and systemic endotoxemia, observed 




Fig.(2): Effect of tributyrin administration on  intestinal tight junction protein 
expression: Mice were pair-fed with either control diet or ethanol (5%v/v) 
containing diet along with tributyrin (2g/kg) orally gavaged. Occludin (green) 
and ZO-1 (red) were visualized by immunohistochemistry in sections of colon 
frozen in OCT. Nuclei were counterstained with DAPI (blue). All images were 




Fig. (3): Effect of tributyin administration on alcohol–induced endotoxemia: 
Mice were pair-fed with either control diet (PF) or ethanol (AF) (5%v/v) 
containing diet along with tributyrin (Tb)(2g/kg) orally gavaged. Serum 
endotoxin levels assessed by biochemical assay were significantly elevated in 
alcohol treated mice and attenuated by tributyrin administration. Data are 
expressed as mean ±SEM, n = 4 to 6 animals/per group. a = compared to 


































Tributyrin attenuates alcohol-induced hepatic steatosis  
Oral administration of tributyrin has been shown to increase concentration of 
butyrate in the portal vein and prevent lipopolysaccharide-induced liver injury in 
rats (Miyoshi	et	al). Since our earlier data showed that tributyrin decreases 
endotoxemia in alcohol fed mice, we examined its effects on hepatic steatosis 
which is a primary pathological consequence of chronic ethanol consumption. 
Histological analysis of the livers as shown by H&E (Fig. 4) and Oil red O (Fig.5) 
staining revealed increase steatosis in livers of chronic alcohol fed mice.  
Interestingly, alcohol intake-induced fat accumulation was significantly attenuated 
by the tributyrin treatment. Effect of tributyrin on hepatic steatosis was further 
confirmed by hepatic triglyceride (Fig.6) and Non-esterified free fatty acids 
(NEFA) analysis (Fig.6). As expected, hepatic triglycerides and free fatty acids 
were increased in alcohol-fed mice compared to pair fed animals However, in 
correspondence with the immunohistochemistry of the livers, tributyrin treatment 
significantly blunted alcohol-induced hepatic triglycerides as well as free fatty 
acids. These results provides compelling evidence that oral administration of 







Fig.(4): Effect of Tributyrin administration on  alcohol-induced fatty liver. Mice 
were pair-fed with either control diet or ethanol (5%v/v) containing diet along 
with tributyrin (2g/kg) orally gavaged. Representative micrographs are shown 
depicting H&E staining (magnification 20X) of liver sections revealing fat 




Fig.(5): Effect of Tributyrin administration on  alcohol-induced fatty liver. Mice 
were pair-fed with either control diet or ethanol (5%v/v) containing diet along 
with tributyrin (2g/kg) orally gavaged. Representative micrographs are shown 
depicting Oil-Red O staining (magnification 20X) of liver sections revealing fat 




Fig.(6): Effect of tributyrin administration on alcohol-induced hepatic steatosis 
as assessed by hepatic free fatty acids and triglyceride : Mice were pair-fed 
with either control diet  (PF) or ethanol (AF) (5%v/v) containing diet along with 
tributyrin (Tb)(2g/kg) orally gavaged.  Data are expressed as mean ±SEM, n = 


































































Tributyrin administration prevents the decrease of CPT-1 gene expression 
in alcohol-fed mice 
We and others have earlier demonstrated that alcohol-mediated down-regulation 
of CPT-1 plays a major role in the development of micro as well as macro-
vesicular steatosis [17-19, 144, 145]. Biochemically, CPT-1 is a rate-limiting 
enzyme in mitochondrial free fatty acid β-oxidation. Hence, to explore the 
potential mechanism through which tributyrin attenuates alcohol-induced hepatic 
steatosis, we examined CPT-1 mRNA levels by real time PCR from animal livers. 
Similar to our binge ethanol model, chronic ethanol feeding also significantly 
suppressed hepatic CPT-1 mRNA expression (Fig. 7) and led to down regulation 
in its protein expression as shown by the anti-CPT-1 staining in liver sections 
(Fig.8). Interestingly, tributyrin administration alone showed the highest 
expression at the mRNA level as compared to pair-fed control and alcohol fed 
animals. These data suggest that tributyrin administration increases β-oxidation 
by increasing hepatic CPT-1 gene expression and thus mitigates alcohol-induced 






Fig.(7): Effect of tributyrin administration on alcohol induced down-regulation 
of CPT-1 gene expression: CPT-1 mRNA levels were significantly down-
regulated in alcohol fed mice and was further restored and increased by 
tributyrin treatment. CPT-1 mRNA levels were analyzed by RT-qPCR and 
normalized to β -actin mRNA. Data are expressed as mean ±SEM, n = 5 





































Fig.(8): Effect of Tributyrin administration on  hepatic CPT-1 protein 
expression in mice liver. Mice were pair-fed with either control diet or ethanol 
(5%v/v) containing diet along with tributyrin (2g/kg) orally gavaged. 
Immunohistochemical staining with anti-CPT-1 antibody (magnification 20X) 
demonstrated that hepatic CPT-1 protein levels (staining) were decreased in 
the liver of alcohol-fed mice and restored by tributyrin administration. 
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Evaluation of Alcohol and Butyrate Mediated Transcriptional Regulation of 
CPT-1 Gene Expression 
To determine the mechanisms underlying the chronic alcohol consumption 
mediated suppression of CPT-1 gene expression and the therapeutic effects of 
butyrate, we performed in vitro analysis using freshly isolated primary 
hepatocytes. As mentioned earlier orally administered tributyrin has shown to 
increase butyrate levels in the hepato-portal circulation. Hence butyrate was 
used in all the in vitro studies. Primary hepatocytes were either left untreated 
(UT) or treated with 50mM ethanol (for 48hrs) with or without sodium butyrate 
(NaB; 2mM). NaB was added 30 min prior to ethanol treatment. The data 
obtained from the primary hepatocytes confirmed our in vivo findings on CPT-1 
gene expression. Indeed, NaB pretreatment not only prevented the alcohol-
induced decrease but further enhanced CPT-1 mRNA expression (Fig. 9).  
Effect of Alcohol and Butyrate on PGC-1 - a key co-activator of CPT-1 gene 
expression 
PGC-1 is an essential transcriptional co-activator of hepatic CPT-1 gene 
expression and is known to be downregulated by alcohol [34, 42, 49]. 48 hours of 
alcohol significantly suppressed PGC-1 gene expression, whereas butyrate pre-
treatment not only reversed but also robustly induced PGC-1 gene expression in 
primary hepatocytes. (Fig.10).  
 Biological effects of butyrate are mediated by its ability to primarily 
function as a Class I/II HDAC inhibitor which can increase histone acetylation 
and activate gene expression [146]. Hence, to address the butyrate effect of 
enhancing PGC-1 mRNA expression, promoter histone acetylation was 
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assessed. Specifically, histone acetylation in the promoter region encompassing 
the cAMP response element (CRE) that binds CREB, a known transcription 
factor for PGC-1 expression was examined (Fig.11). Chromatin was prepared 
from the rat primary hepatocytes treated with alcohol 50mM and with/without 
pretreatment with NaB 2mM as well as from NaB alone for 12hours. ChIP 
analysis was performed using an Ab that selectively recognizes H3K9Ac. 
Commensurate with its effect on PGC-1 mRNA, butyrate was observed to 
prevent alcohol induced decrease in promoter H3K9Ac levels and in fact 








Fig.(9): Effect of butyrate on  alcohol mediated down-regulation of CPT-1 gene 
expression. Primary hepatocytes were untreated (UT) or treated with 50mM 
alcohol (A) for 48h. Cells were pretreated with sodium butyrate for 30 min prior 
to alcohol. CPT-1 mRNA levels were analyzed by RT-qPCR and normalized to 
β-actin mRNA. Data are expressed as mean ±SEM, n = 3. a = compared to 





































   
Fig.(10): Effect of butyrate on  alcohol mediated down-regulation of PGC-1 gene 
expression Primary hepatocytes were untreated (UT) or treated with 50mM 
alcohol (A) for 48h. Cells were pretreated with sodium butyrate for 30 min. PGC-1 
mRNA levels were analyzed by RT-qPCR and normalized to β-actin mRNA. Data 





































Transcription start site (TSS) 
	
Schematic of PGC-1 promoter 
Fig.(11) PGC-1 promoter schematic. Location of ChIP PCR primer pair for 
analysis of epigenetic modifications is shown in the schematic with respect to 




Fig.(12) H3K9Ac enhancement at PGC-1 promoter by butyrate: Primary 
hepatocytes were untreated (UT) or treated with 50mM alcohol for 12h. 
Sodium butyrate was pretreated for 30 min. Chromatin fragments were 
immunoprecipitated with H3K9Ac antibody and ChIP-qPCR was performed 
using primer pair specific for TSS site on PGC-1 promoter. A representative 










Schematic of CPT-1 promoter 
promoter
Fig.(13) CPT-1 promoter schematic: Locations of key transcriptionally active regions 
and ChIP PCR primer pairs for analysis of epigenetic modifications are denoted. The 




Effect of Alcohol and Butyrate on CPT-1 Transcriptional Mechanisms 
Effect on the recruitment of co-activators PGC-1and p300 
 PGC-1 is a key transcriptional coactivator of CPT-1 gene expression. As a 
coactivator, PGC-1 can recruit and facilitate interactions with other coactivators 
such histone acetyl transferases (HATS; e.g. SRC-1, p300) that can induce 
chromatin remodeling via histone acetylation [147, 148]. Hence, in correlation 
with the observed CPT-1 and PGC-1 mRNA expression we examined the effect 
of alcohol and butyrate on PGC-1 and p300 protein recruitment to the 
transcriptionally relevant CPT-1 promoter regions denoted as DR-1 site and SP-1 
site (Fig. 13) Chromatin from alcohol and NaB treated hepatocytes was obtained 
as mentioned above and ChIP analysis was performed using PGC-1 specific 
antibodies. Relative to CPT-1 mRNA expression, alcohol decreased PGC-1 
binding which was prevented by NaB (Fig.14). Following PGC-1, recruitment of 
HAT - p300 to the relevant CPT-1 promoter region was evaluated. Proportional to 
PGC-1 recruitment and its coactivator function, alcohols diminishing effect on 
p300 binding was counteracted by NaB resulting in an increase in its binding 
(Fig.15). 
 Subsequent to examining the effects of alcohol and butyrate on PGC-1 and 
p300 recruitment, we examined their effect on promoter histone modifications as 
pertinent epigenetic mechanisms dictating CPT-1 transcription.   Promoter 
histone modifications were examined by ChIP qPCR analysis [149] using PCR 
primer sets for region that overlaps the transcription state site (TSS site). 
Specifically, the status of histone H3 lysine 9 acetylation (H3K9Ac) was assessed 
which plays a key role in the transcriptional activation of gene expression.  
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Chromatin from primary hepatocytes treated with ethanol and NaB was 
evaluated by ChIP analysis by using an Ab that selectively recognizes H3K9Ac. 
Commensurate with the observed decrease in CPT-1 mRNA levels as well as 
PGC-1 and p300 binding, ethanol treatment led to a decrease in the promoter 
H3K9Ac levels indicative of a transcriptionally repressive chromatin state. In 
comparison, NaB pre-treatment not only inhibited the ethanol induced decrease, 
but also increased H3K9Ac levels over base-line. Interestingly, NaB alone 
markedly increased CPT-1 promoter H3K9Ac levels and induced CPT-1 
transcription (Fig.16). These data suggest that the protective effect of NaB is 

































Fig: (14) Increase in PGC-1 binding at the CPT-1 promoter by butyrate: Primary 
hepatocytes were untreated (UT) or treated with 50mM alcohol for 12h. Sodium 
butyrate was pretreated for 30 min prior to alcohol. Chromatin fragments were 
immunoprecipitated with PGC-1 antibody and ChIP-qPCR was performed using 
primer pair specific for DR-1 site on CPT-1 promoter. Representative PCR data 





Fig.(15)  Increase in p300 recriuitment by PGC-1 at the CPT-1 promoter by 
butyrate: Primary hepatocytes were untreated (UT) or treated with 50mM 
alcohol for 12h. Sodium butyrate was pretreated for 30 min. Chromatin 
fragments were immunoprecipitated with p300 antibody and ChIP-qPCR was 
performed using primer pairs specific for DR-1 site on CPT-1 promoter.  
Representative PCR data is shown. Non-immunoprecipitated chromatin was 




Fig.(16) Increase in H3K9Ac levels at the TSS site of the CPT-1 promoter by 
butyrate: Primary hepatocytes were untreated (UT) or treated with 50mM 
alcohol for 12h. Sodium butyrate was pretreated for 30 min prior to alcohol. 
Chromatin fragments were immunoprecipitated with H3K9Ac antibody and 
ChIP-qPCR was performed using primer pairs specific for TSS site and   SP-1 
site on CPT-1 promoter. A representative PCR data is shown. Non-
immunoprecipitated chromatin was used as input.  
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Effect on CPT-1 transcription pre-initiation complex 
Earlier studies have demonstrated that CPT-1 is a TATA-less gene and 
transcription factor Sp1 is significantly involved in the regulation of basal as well 
as inducible transcriptional activation of CPT-1 gene expression [43, 44]. Hence, 
having determined the impact of alcohol and butyrate on the recruitment of co-
activators and promoter histone acetylation affecting CPT-1 mRNA expression, 
we then examined the effects on Sp1 and RNA Pol II binding that constitutes the 
relevant components of the CPT-1 transcription pre-initiation complex.  
Chromatin from primary hepatocytes treated with ethanol and NaB was 
evaluated by ChIP analysis by using antibodies that selectively recognize Sp1 
and RNA Pol II. Sp1 binding was examined at Sp1 site and RNA PolII binding 
was examined at the TSS site (Fig.13). In correlation with the decrease in CPT-1 
mRNA expression, alcohol induced a disruption of the transcriptional pre-
initiation complex as indicated by the decline in transcription factor - Sp1 binding 
and recruitment of RNA Pol II at the CPT-1 promoter (Fig.17, 19). Importantly, 
butyrate in correlation with an increase in CPT-1 promoter histone acetylation 
indicative of an increase in the transcriptionally active state, led to an increase in 
Sp1 binding and RNA Pol II recruitment and recommencement of the formation 
of the transcriptional pre-initiation complex. Moreover Sp1 is known to promote 
transcription by interacting and recruiting p300 [150]. Indeed, a butyrate 
mediated increase in p300 binding to the Sp1 region of the CPT-1 promoter was 
also observed in alcohol treated hepatocytes (Fig.18).    
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These data strongly suggest that p300 recruitment via Sp1, besides PGC-1, 
could have also contributed to the net dynamic increase in CPT-1 promoter 
histone acetylation and transcriptional activation.  
Overall, oral administration of tributyrin significantly protects gut barrier 
function and attenuates chronic alcohol-induced hepatic steatosis. Specifically, 
tributyrin induces transcriptionally permissive chromatin modifications at the 
CPT-1 promoter and thus improves CPT-1 gene expression and β-oxidation in 


































Fig.(17) Increase in Sp-1 binding at the Sp-1 site on the  CPT-1 promoter by 
butyrate: Increase in PGC-1 binding at the CPT-1 promoter by butyrate Primary 
hepatocytes were untreated (UT) or treated with 50mM alcohol for 12h. Sodium 
butyrate was pretreated for 30 min. Chromatin fragments were 
immunoprecipitated with SP-1 antibody and ChIP-qPCR was performed using 
primer pair specific for SP-1 site on CPT-1 promoter. Representative PCR data 





Fig.(18) Increase in p300 recruitment by SP-1 at the SP-1 site on the CPT-1 
promoter: Primary hepatocytes were untreated (UT) or treated with 50mM 
alcohol for 12h. Sodium butyrate was pretreated for 30 min. Chromatin 
fragments were immunoprecipitated with p300 antibody and ChIP-qPCR was 
performed using primer pairs specific for SP-1 site on CPT-1 promoter.  
Representative PCR data is shown. Non-immunoprecipitated chromatin was 




Fig.(19) Increase in RNA pol II at the TSS site on the CPT-1 promoter: Primary 
hepatocytes were untreated (UT) or treated with 50mM alcohol (A) for 12h. 
Sodium butyrate was pretreated for 30 min. Chromatin fragments were 
immunoprecipitated with RNA-Pol II antibody and ChIP-qPCR was performed 
using primer pair specific for TSS site on CPT-1 promoter.  Representative PCR 
data is shown. Non-immunoprecipitated chromatin was used as input to 

































Tributyrin administration protects from alcohol-induced hepatic 
inflammation and injury 
Studies have shown that 10-30% heavy drinkers progresses from hepatic 
steatosis to hepatic inflammation and injury. Activation of innate immune 
response either by kupffer cells which are resident macrophages or infiltrating 
macrophages and resultant pro-inflammatory cytokine production such as TNF-α, 
IL-8, IL-1β have been well documented in alcoholic liver disease. Since tributyrin 
showed protection against alcohol induced steatosis we next investigated its 
impact on hepatic inflammation and injury.  
Tributyrin inhibits the alcohol-mediated macrophage activation and pro-
inflammatory cytokine -TNF-α expression 
The effect of tributyrin on macrophage activation was evaluated by 
immunohistochemistry for F4/80-positive macrophages in the liver tissue 
(Fig.20). Data showed that there are more F4/80 positive macrophages as seen 
by brown stained cells in alcohol fed animals but that number was markedly less 
in the tributyrin and alcohol together treated mice. Additionally, the macrophage 
activation was further confirmed by measuring pro-inflammatory cytokine, tumor 
necrosis factor-α (TNF-α) production (Fig.21). In accordance with macrophage 
activation, the TNF-α mRNA levels were high at 2 weeks alcohol feeding but 
were significantly decreased in mice that received tributyrin administration along 
with alcohol feeding. Tributyrin alone did show marginal increase in TNF-α 




Butyrate down-regulated LPS inducible TNF-a gene expression in RAW 
cells 
Since increase TNF-α expression was seen in two week alcohol fed animals and 
Aldred et al. have shown that after chronic alcohol consumption, 
macrophages/Kupffer cells demonstrate enhanced LPS-stimulated TNF-α 
production[151]. We next examine the effect of butyrate on LPS inducible TNF-α 
gene expression in RAW cells (Fig.22). The data showed that LPS (100ng/ml) 
treatment caused robust upregulation (~ 20 fold) in the TNF-α mRNA levels as 
compared to untreated cells; however the Na-butyrate (1mM) pretreatment 
inhibited LPS-stimulated TNF-α gene expression. These data further support the 








Fig.(20) Effect of tributyrin administration on F4/80
  
positive cells in mice 
chronically fed alcohol for 2 weeks. Representative micrographs are shown 
depicting F4/80 staining of liver sections revealed increased macropage 





Fig.(21) Chronic alcohol-induced TNF-α gene expression: Alcohol significantly 
induced TNF-α gene expression which was attenuated by tributyrin treatment. 
TNF-α mRNA levels were analyzed by RT-qPCR and normalized to β -actin 
mRNA. Data are expressed as mean ±SEM, n = 5 animals/per group.               

































Fig.(22) LPS inducible TNF-α gene expression in RAW 264.7: LPS (100ng/ml) 
inducible TNF-α gene expression was attenuated by butyrate 2mM tributyrin 
treatment. TNF-α mRNA levels were analyzed by RT-qPCR and normalized to      
β-actin mRNA. Data are expressed as mean ±SEM, n =3.  a = UT and b = LPS  























Tributyrin administration significantly attenuates chronic alcohol-induced 
MCP-1 (CCL-2) gene expression in mice and rat hepatocytes  
MCP-1 upregulation plays a critical pathogenic role in the progression of alcohol-
induced hepatic inflammation and injury in C57BL/6 mice as well as alcoholic 
hepatitis patients [93]. Hence in our animal model we investigated the effect of 
tributyrin/butyrate on the alcohol-induced regulation CCL-2 gene expression. In 
this model C57BL/6 mice were fed the Leiber-Decarli diet or its isocaloric control 
(Pair-fed PF) to determine the expression of CCL-2 in the whole liver. Two weeks 
of chronic alcohol feeding significantly induced (~3 fold) CCL-2 gene expression 
in the liver. This CCL-2 induction was further upregulated (~7 fold) at the end 7 
weeks. Tributyrin co-administration markedly suppressed the induction of 
alcohol-induced hepatic CCL-2 at 2 as well as 7 weeks of alcohol feeding to 
baseline pair-fed level (Fig.23). To isolate the role of hepatocytes in the alcohol-
induced CCL-2 expression, rat primary hepatocytes were treated with alcohol 
(50mM) for 48hrs and TNF-α (20ng/ml) for 4 hrs. with/without pretreatment of 
butyrate (2mM, 30min). TNF-α exposure alone induced ~10 fold up-regulation in 
CCL-2 gene expression over untreated. Moreover, alcohol further primed the 
cells to TNF-α induced CCL-2 expression upto~35 fold as compared to untreated 
cells. Pre-treatment with NaB significantly attenuated CCL-2 gene expression 
induced in response to TNF-a as well as combination of alcohol and TNF-α 
treatment (Fig. 24). These data indicates that tributyrin administration 
significantly down-regulates chronic-alcohol induced CCL-2 gene expression in 
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the whole liver as well as in CCL-2 producing hepatocytes leading to decrease in 











Fig.(23)Chronic alcohol induced CCL2 gene expression in alcohol fed mice: 
CCL2 mRNA levels were up-regulated in alcohol fed mice livers and was 
attenuated by tributyrin treatment. CCL2 mRNA levels were analyzed by RT-
qPCR and normalized to β-actin mRNA. Data are expressed as mean ±SEM, 
n = 5 animals/per group.  p value a = when compared to control and b = when 















Fig.(24) Chronic alcohol induced CCL2 gene expression in rat primary 
hepatocytes: Hepatocytes were treated with alcohol 50mM for 48hrs and TNF-
α (20ng/ml) for 4hrs with/without Sodium butyrate (NaB). CCL2 mRNA levels 
were analyzed by RT-qPCR and normalized to β-actin mRNA. Data are 
expressed as mean ±SEM, n = 3. p value a when compared to control; b when 
compared to TNF-α; d when compared to alcohol and e when compared to 
Alcohol +TNF-α.  
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Tributyrin administration significantly attenuates chronic alcohol-induced 
CXCL-2 (MIP-2) gene expression in mice 
One of the key pro-inflammatory cytokines involved in modulating the 
inflammatory response is the CXC chemokine interleukin-8 (IL-8), which 
functions as a critical chemoattractant and activator for neutrophils, basophils, 
and T cells. Sustained consumption of ethanol was shown to be associated with 
elevated serum as well as hepatic MIP-2 [87, 152]. Hence we examined the 
expression of CXCL2 in the alcohol-fed mice with/without tributyrin co-
administration. Two weeks of alcohol-feeding did not induce CXCL2 gene 
expression in the liver although a trend was observed. However, sustained 
alcohol consumption upto 7 weeks significantly induced CXCL-2 gene 
expression. This alcohol-induced CXCL2 gene expression was significantly 
suppressed by tributyrin administration suggesting that tributyrin attenuated 



















Fig.(25) Chronic alcohol induced chemokine CXCL2 gene expression: CXCL2 
mRNA levels were up-regulated in alcohol fed mice and were attenuated by 
tributyrin treatment. CXCL2 mRNA levels were analyzed by RT-qPCR and 
normalized to β-actin mRNA. Data are expressed as mean ±SEM, n = 5 
animals/per group. p value a = control and b = when compared to alcohol.  
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Tributryin administration significantly down-regulates adhesion molecule  
(ICAM-1) in alcohol-fed mice 
It has been shown ICAM-1 plays an important role in alcohol-induced liver 
injury by facilitating adhesion of leukocytes such as neutrophils [78]. In our 
chronic alcohol feeding model ICAM-1 mRNA expression was significantly 
induced compared to pair-fed controls. Tributyrin co-administration significantly 
decreased alcohol-induced ICAM-1 gene expression in C57BL/6 mice        
(Fig. 26).   
Tributyrin administration decreases neutrophil infiltration in alcohol-fed 
mice  
Neutrophil infiltration is a hallmark of hepatic inflammation. The above data show 
that expression of MCP-1 and MIP-2, which are potent chemoattractants for 
monocytes and/or neutrophils, was unregulated after chronic-alcohol feeding. 
Therefore, we stained the liver with CAE to scan neutrophils infiltration. As 
expected, seven weeks of alcohol exposure increased hepatic neutrophils. 
However, tributyrin administration suppressed neutrophil infiltration as seen by 
decreased CAE staining (Fig. 27). Neutrophil infiltration was further confirmed by 
MPO activity assay. MPO activity was significantly increased in alcohol-fed mice 
at 7 weeks of alcohol feeding (Fig. 28). Tributyrin co-administration significantly 
reduced MPO activity in the liver. This data indicate that tributyrin administration 




















Fig.(26) Chronic alcohol-induced chemokine ICAM-1 gene expression: ICAM-1 
mRNA levels were up-regulated in alcohol fed mice and was attenuated by 
tributyrin treatment. ICAM-1 mRNA levels were analyzed by RT-qPCR and 
normalized to β-actin mRNA. Data are expressed as mean ±SEM, n = 5 




































Fig.(27) Effect of tributyrin administration on liver histopathology in mice 
chronically fed alcohol for 7 weeks. Representative micrographs are shown 
depicting CAE staining of the liver sections revealing neutrophil infiltration in the 






Fig.(28) Hepatic MPO activity in response to alcohol and tributyrin: Hepatic 
MPO activity in mice was significantly elevated in 7 weeks of alcohol feeding 
and attenuated by tributyrin treatment. Data are expressed as mean ±SEM,  
n = 4 to 6 animals/per group. a = compared to control, b = compared to alcohol.  
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Administration of Tributyrin attenuated Aspartate Transaminase (AST) and 
Alanine Transaminase (ALT) in alcohol-fed mice 
Serum ALT and AST levels are the hallmark of liver injury. It has been well 
documented that chronic as well as binge alcohol consumption increases AST 
and ALT levels in the blood indicating liver injury. Hepatic steatosis and 
inflammation predisposes the liver to cause injury. Hence we measured serum 
AST and ALT levels in these mice and as expected AST and ALT levels were 
significantly elevated compared to pair-fed control mice. Co-administration of 
tributyrin along with alcohol markedly suppressed AST and ALT in mice. This 
data demonstrates that along with markedly reducing alcohol-induced 
inflammatory responses in the liver, tributyrin administration attenuated 

















Fig.(29) Effect of tributyrin administration on liver injury  in mice chronically fed 
alcohol for 7 weeks: ALT and AST activity was significantly elevated in 7 weeks 
of alcohol feeding mice and markedly attenuated by tributyrin treatment. Data are 
expressed as mean ±SEM, n = 4 to 6 animals/per group. a = compared to 























Understanding the pathophysiology and the mechanisms of chronic 
alcohol-mediated steatosis and steatohepatitis has led to the advancement of 
new preventive and beneficial strategies in treating alcoholic liver disease. 
Recent studies have shown that alcohol decreases short-chain fatty acids 
(SCFAs) [153]. SCFAs, predominantly acetate, propionate and butyrate, are the 
end-products of anaerobic bacterial fermentation of carbohydrates in the colon. 
SCFAs, especially butyrate, play important roles in the biology of colonocytes, by 
acting as the principal energy source and maintaining the integrity of the 
intestinal environment [122, 154]. Tributyrin is a butyrate prodrug, and oral 
administration of tributyrin has been shown to increase butyrate concentration in 
the hepato-portal circulation [155]. Hence the present study examined the role of 
tributyrin supplementation in the prevention of alcohol-induced hepatic steatosis, 
inflammation and injury. 
Alcohol consumption causes gut microbial dysbiosis and affect intestinal 
tight junction protein expression leading to systemic endotoxemia [156]. Since 
tributyrin is metabolized to butyrate by the intestinal bacteria and pancreatic 
lipases and has been shown to have protective effects on gut barrier integrity we 
initially investigated the role of orally administered tributyrin on intestinal ileum 
tight junction. In accordance to the previous studies [156], tributyrin 
supplementation prevented the loss of alcohol-induced TJ proteins.  Previous 
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studies have shown that butyrate treatment improves TJ protein expression by 
AMPK [157]. Chronic alcohol exposure can decrease the phosphorylation of 
AMPK leading to its inactivation. Butyrate could be increasing phosphorylation of 
AMPK during chronic alcohol exposure. This could be a possible mechanism by 
which butyrate improves the alcohol-mediated suppression of TJ-proteins. In 
accordance to the literature, alcohol increased systemic endotoxin and was 
significantly attenuated by tributyrin co-administration. 
Hepatic steatosis predisposes the liver to second hits and injuries allowing the 
progression to severe forms of disease. Alterations in the gut-liver axis are 
known to drive liver damage. Importantly, it has been shown that oral 
administration of tributyrin increases the concentration of butyrate in the 
hepatoportal vein exerting its beneficial effects on the liver [155]. Since we 
observed tributyrin protection on gut associated changes, we further examined 
the effect of tributyrin on liver. Immunohistochemical staining and biochemical 
parameters of hepatic steatosis such as hepatic triglycerides and free fatty acids 
were significantly reduced by tributyrin. Hepatic triglyceride accumulation and 
steatosis can occur as a consequence of increased fatty acid synthesis as well 
as decreased β-oxidation of fatty acids. Recent studies have shown that alcohol 
consumption affects both these pathways in hepatic steatosis [7, 158, 159]. 
Previous studies from our lab have shown that a decrease in CPT-1 plays a 
critical role in binge alcohol-induced hepatic steatosis [17, 145]. Notably, in the 
present study Tributyrin/butyrate treatment not only reversed CPT-1 gene 
expression in chronic alcohol-fed mice and primary hepatocytes but also 
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augmented its baseline expression. Because CPT-1 catalyzes a rate limiting step 
in mitochondrial free fatty acid β-oxidation, upregulation by tributyrin/butyrate is a 
significant contributory factor in preventing the development of chronic alcohol-
induced liver steatosis. Hence we further investigated the mechanisms 
underlying the therapeutic effects of butyrate on CPT-1 gene expression by 
alcohol. 
PGC-1 is shown to be a critical co-activator in regulating CPT-1 gene 
expression [160]. Importantly, it has been reported that PGC-1deficiency leads to 
the development of hepatic steatosis whereas overexpression of PGC-1 alone is 
sufficient to induce CPT-1 transcription. Butyrate treatment robustly induced 
PGC-1 gene expression in the alcohol treated cells indicating that increase in 
PGC-1 could be a major player in tributyrin mediated up-regulation of CPT-1. In 
the context of CPT- 1 transcriptional activation, PGC-1 acts as a co-activator and 
interacts with transcription factors such as PPAR-α, HNF4α increasing promoter 
histone acetylation [42][35][34]. Interestingly, alcohol treatment was observed to 
decrease PGC-1 recruitment only at the HNF4α binding region (DR-1 site) 
(fig.15) with minimal to no effect at the PPAR-α binding site (PPRE site) (data not 
shown). These data indicate that butyrate mediated transcriptional activation of 
CPT-1 occurs in a PPAR-α independent manner. her paper)  . A significant 
component of butyrate’s biological activity is its ability to inhibit HDACs. The role 
of butyrate as a HDAC inhibitor was evaluated on acetylation state of the CPT-1 
and PGC-1 promoter. Particularly, the states of H3K9Ac were assessed since 
this histone modification plays a key role in establishing transcriptionally 
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permissive chromatin states. Specifically, H3K9Ac actively neutralizes the basic 
charge of the affected lysine and ultimately leads to chromatin de-condensation, 
making the DNA more accessible to transcription factors and RNA polymerases 
leading to gene transcription. HDAC inhibitory property of butyrate increased the 
H3K9 acetylation in the alcohol treated cells at TSS site on the CPT-1 and PGC-
1 promoter. The data obtained strongly supports that the changes in PGC-1 and 
CPT-1 promoter H3K9Ac levels is achieved by the butyrate HDAC inhibitory 
function. Additionally, the data support the notion that butyrate mediated increase 
in H3K9Ac results into active transcription as seen by up regulation in CPT-1 and 
PGC-1 mRNA levels.  
The states of CPT-1 promoter H3K9Ac can be significantly enhanced by 
PGC-1 co-activator function. PGC-1 is known to interact and recruit HATS such 
as SC-1 and p300 [147, 148]. Besides PGC-1, p300 HAT can also be recruited 
by the TF SP-1 which plays a role in maintaining the basal and inducible CPT-1 
gene expression [150]. P300 is a well-known histone acetyl transferease (HAT) 
and co-activator that plays a pivotal role in the transcription regulation of gene 
expression [161, 162]. Indeed, commensurate with the butyrate mediated 
increase in PGC-1 binding and H3K9Ac levels at the CPT-1 promoter, there was 
an increase in the recruitment of p300. This reflected by the transcriptionally 
permissive state of the CPT-1 promoter. This was shown by an increase in the 
assembly of the pre-initiation complex represented by increased   Sp-1 binding 
and RNA-polymerase II. It is noteworthy that Sp-1 binds and recruits p300 HAT 
and further influence the transcriptional state. According it is possible increase 
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sp-1 binding would further contribute to a net increase in the histone acetylation 
state of the promoter ultimately contributing to transcriptional activation of CPT-1 
gene.  
 Overall, this data confirms the role of butyrate as an HDAC inhibitor by 
increasing the net histone acetylation state of the CPT-1 promoter thereby 
recruiting co-activators PGC-1 and p300 along with TFs and RNA-Pol II, 
engaging the transcription machinery required for CPT-1 gene expression.  
Further, after confirming the role of butyrate in alcohol-induced hepatic 
steatosis we investigated the effect of tributyrin/butyrate on alcohol-induced 
hepatic inflammation. TNF-α, a key cytokine involved in the development of 
alcoholic liver disease was significantly down-regulated by tributyrin 
administration as early as 2 weeks indicating that butyrate suppresses initial 
inflammation caused due to alcohol consumption. Additionally, chemokines such 
CCL-2/MCP-1 has been shown to be significant factors in various chronic 
inflammatory diseases [163]. Recent studies have shown that MCP-1 regulation 
shares a common link between inflammatory cytokines and lipid metabolism in 
alcoholic liver disease [93]. In our animal model we have shown that CCL-2 was 
induced by 2 weeks of alcohol-feeding and its high expression was maintained 
up to 7 weeks. This indicates that CCL-2 regulation is involved in sustained 
inflammation. Moreover, alcohol primed the hepatocytes and increases their 
sensitivity to TNF-α inducible CCL-2 expression. Butyrate significantly down-
regulated CCL-2 induction indicating that butyrate can directly act on the 
hepatocytes to suppress inflammatory chemokines. Potentially, butyrate being as 
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HDAC inhibitor, could also be affecting acetylation of non-histone proteins 
including certain transcription factors responsible for the induction of CCL-2.  
NFκB is known to play a central role in immune and inflammatory responses and 
is involved in transcriptional regulation of many chemokines and cytokines 
including TNF-α. Suppression of LPS inducible TNF-α by butyrate in RAW cells 
indicated that butyrate inhibits pro-inflammatory cytokine production in 
macrophages. Hence we speculate that butyrate inhibits NFκB activation via 
affecting its acetylation state and/or promoting IκBα degradation [133] leading to 
resultant down-regulation of CCL-2 gene expression.  In addition to NFκΒ, CCL-2 
is also regulated by Activator protein-1. Hence butyrate could suppress CCL-2 
expression by decreasing the DNA binding activity of NFκB and AP-1 onto the 
CCL-2 promoter. Immunohistochemical analysis showed that butyrate 
suppressed alcohol-induced neutrophil infiltration and macrophage activation as 
shown by F4/80+ cells. Finally liver injury markers, AST and ALT were 
significantly down-regulated by triburyrin administration indicating that tributyrin 
prevented alcohol-induced early liver injury at 2 weeks as well as sustained injury 
at 7 weeks. 
Overall this data indicates that tribtyrin/butyrate through HDAC inhibition 







SUMMARY AND CONCLUSIONS 
Work done in this thesis examines the role and the underlying molecular 
mechanisms of Tributyrin in the attenuation of Alcoholic liver disease in mice. 
Decades of research have shown that chronic alcohol abuse is associated with 
alcoholic liver disease (ALD). Clinically, stages of alcoholic liver disease include 
fatty liver, steatohepatitis followed by fibrosis and cirrhosis leading to 
hepatocellular carcinoma. Hepatic steatosis is transient and temporary. If not 
treated, it can progress into steatohepatitis leading to the development of 
alcoholic liver disease. There is no FDA-approved therapy for any stage of 
alcoholic liver disease.  Hence it is of prime importance to understand the 
mechanisms of Alcoholic liver disease which would lead us to a better 
understanding of therapeutic intervention and further developing novel 
strategies/therapies in the treatment of ALD. Hence in this project, we have 
investigated the effects of Tributyrin supplementation; a pro-drug of butyrate in 
attenuating alcohol induced hepatic steatosis, inflammation injury in mice. 
Previous studies have shown that increase in the butyrate levels in the hepato-
portal circulation prevents LPS-induced liver injury in rats. The hypothesis of this 
project is that oral administration of tributryin targets the ‘gut-liver’ axis and 
significantly blocks the progression of alcoholic liver disease (ALD). 
We have used a well-established animal model of alcoholic liver disease 
to examine the effects of Tb oral administration on ethanol-induced changes in 
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intestinal permeability and hepatic steatosis, inflammation and injury. 8–10-week 
old C57BL/6 male mice were pair-fed the Lieber-DeCarli liquid diet containing 
alcohol or isocaloric maltose dextrin for a period of 7 weeks. Tributyrin was 
administered to a sub-group of alcohol-fed animals by oral gavage to assess its 
effects. In order to monitor the temporal changes in the progression of ALD, 
these animals were sacrificed at 2, 4 and 7 weeks.  
Initial analysis revealed Tributyrin attenuated the ethanol-induced gut 
barrier dysfunction, as shown by the significant reduction in endotoxemia. 
Mechanisms of chronic alcohol-induced gut-barrier dysfunction were examined 
by the immune-histochemical analyses of the ileum section of mice chronically 
fed alcohol. Specifically, alcohol induced a robust down-regulation of intestinal 
tight junction proteins ZO-1 and occludin which was markedly attenuated by 
Tributyrin. Additionally, Tributyrin treatment significantly decreased alcohol 
induced hepatic steatosis as well as hepatic triglycerides. Tributyrin prevented 
ethanol-induced down-regulation of CPT-1 gene expression (RT-PCR), a key 
enzyme in fatty acid β-oxidation. Tributyrin being a prodrug is metabolized to 
butyrate by pancreatic lipases. Butyrate is a HDAC inhibitor. To understand the 
regulation of CPT-1 gene expression under pathogenic conditions experiments 
were performed using primary rat hepatocytes. Hence acetylation at CPT-1 
promoter was investigated. Acetylation of histone 3 lysine 9 (H3K9), a critical 
feature of the active promoter state was suppressed by alcohol treatment in 
hepatocytes reversed by butyrate. PGC-1 a critical co-activator of CPT-1 and Sp-
1, transcription factor binding to DNA was robustly increased by butyrate. 
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Additionally, p300 a histone acetyl transferase was shown to be recruited at the 
DR-1 binding site as well as TSS site on the CPT-1 promoter region indicating an 
increase in the net acetylation. Hence butyrate being an HDAC inhibitor 
increases the net acetylation state at the promoter region of CPT-1 gene leading 
to its transcriptional activation and regulation.  
  Hepatic inflammation was markedly decreased in Tributyrin administered 
alcoholic mice seen by liver immunohistochemistry staining. Myeloperoxidase 
activity, a quantifiable measure of inflammation was significantly dampened by 
Tributyrin. Tributyrin also attenuated the ethanol induced hepatic expression of 
the critical inflammatory cytokine, TNF-α. Liver injury markers such as AST and 
ALT were significantly attenuated at the end of 7 weeks in Tributyrin treated 
mice. Moreover, Tributyrin also prevented the ethanol-induced expression of 
chemo-attractant chemokines (CXCl2, CCl2 and ICAM-1), and neutrophil 
recruitment that are critical for the development of ALD. Future studies are aimed 
to understand the underlying mechanisms of how butyrate protects the gut and 
the liver in alcohol fed animals. 
Overall, the present work demonstrates that tributyrin may be useful in 
preventing the ethanol-induced gut barrier dysfunction and associated pathologic 
hepatic changes, and may prove to be a useful therapy for the 














DETERMINE THE MECHANISMS OF HIV-ANTIRETROVIRAL 













HIV/AIDS- An overview 
HIV (Human Immunodeficiency Virus) infection is considered pandemic by 
the World Health Organization (WHO), claiming more than 25 million lives over 
the past three decades. Thirty four million people are affected worldwide. Centre 
for Disease Care (CDC) estimates 1.2 million people in the United States (US) 
are living with HIV infection (www.cdc.gov). One in five (20%) of those people are 
unaware of their infection. By race, African Americans face the most severe HIV 
burden. Men having sex with men (MSM), particularly the young, are most 
severely affected. HIV infection leads to AIDS (Acquired Immunodeficiency 
Syndrome). AIDS was first recognized in the United States in the summer of 
1981, when the U.S. (CDC) reported the unexplained occurrence of 
Pneumocystis jiroveci (formerly P. carinii) pneumonia in five previously healthy 
homosexual men in Los Angeles. In 1983, human immunodeficiency virus (HIV) 
was isolated from a patient with lymphadenopathy, and by 1984 it was 
demonstrated clearly to be the causative agent of AIDS. Since the epidemic 






HIV and HAART 
In order to prevent or delay resistance development in HIV infected 
patients, physicians are using a regimen which consists of a combination of 
several types of antiretroviral drugs that act on different sites on a retro virus and 
also target different stages in the lifecycle of the virus. Such treatments are called 
highly active antiretroviral therapy (HAART) [164]. The development of multi-drug 
combination therapy for treatment of HIV disease is considered one of the great 
success stories of modern medicine. In a period of approximately ten years, the 
death rate from HIV disease was reduced by 50 to 80% [165]. HAART as 
treatment for HIV infection has greatly improved mortality and morbidity for adults 
and children living with HIV around the world [166, 167]. HAART is the only 
treatment available to suppress the viral load. Currently used HAART medication 
include nucleoside reverse transcriptaseitnhibitors (NRTIs) (zidovudine, 
didanosine, abacavir), non-nucleoside reverse transcriptase inhibitors (NNRTI) 
(nevirapine, etravirine), protease inhibitors (PI) (indinavir, ritonavir, lopinavir, 
atazanavir), Fusion inhibitors (Enfuvirtide), Integrase Inhibitors (Raltegravir), and 
CCR5 inhibitors all of which act on different sites on HIV facilitating a decrease in 
viral load. Current treatment guidelines strongly recommends the use of triple-
drug regimens which consists of two nucleoside reverse transcriptase inhibitors 
(NRTIs) with either a protease inhibitor (PI) or a non-nucleoside reverse 
transcriptase inhibitor (NNRTIs) as a first line option for the initial treatment of 
early and advance disease progression [95]. Since the introduction of highly 
active antiretroviral therapy (HAART) in the mid-1990s, the life expectancy of 
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patients with HIV has increased significantly [168, 169]. Although HAART has 
been widely used in the treatment of HIV, HIV infected patients have experienced 
complications associated with HAART, which cannot be ignored. Antiretroviral 
toxicity, resistance, and adherence rank high on the list of problems that must be 
overcome if all, or at least the vast majorities, of HIV-infected patients are to gain 
the long-term benefits associated with HAART [170]. Among these problems, 
toxicity, real or perceived, is a major reason for patients either refusing or 
prematurely discontinuing HAART [171]. The drop in mortality and morbidity due 
to opportunistic infection has been accompanied by a concomitant increase in 
HAART-related hepatotoxicity which caused discontinuation of HAART in 
increasing numbers of patients. HAART hepatotoxicity, including lactic acidosis, 
hepatic steatosis and lipodystrophy, occurs in approximately 10% of patients and 
is higher in those with underlying liver disease [172].  
Nucleoside Reverse Transcriptase Inhibotors (NRTI)- Nucleoside/nucleotide 
reverse transcriptase inhibitors (NRTIs), inhibit the formation of viral DNA by 
incorporating into the newly formed DNA molecules, thereby preventing further 
elongation of those molecules [173].  
Protease Inhibitor (PI) - Protease inhibitors block the activity of the protease 
enzyme, which HIV uses to degrade large polyproteins into the smaller pieces 
required for assembly of new viral particles. All PIs are metabolized in the liver by 
CYP3A isoenzymes; consequently their metabolic rates may be altered in the 
presence of CYP inducers or inhibitors. Co-administration of PIs with a potent 
CYP3A inducer may lead to suboptimal drug concentrations and reduced 
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therapeutic effects of the PI. Hence co-administration of PIs with ritonavir (RTV), 
a potent CYP3A inhibitor will optimally increase PI exposure. [174]. While HIV 
can still replicate in the presence of protease inhibitors, the resulting virions are 
immature and unable to infect new cells. PI –based regimen has seen 
demonstrated to have anti-virologic potency. Unlike NRTI resistance, virologic 
failure rarely selects for PI-resistance, which confers it with increased efficiency 
in decreasing the viral load. 
Ritonavir and Lopinavir- Protease inhibitors 
Lopinavir is a novel PI developed from ritonavir. It is structurally related to 
ritonavir with the same mechanism of action. Lopinavir has poor oral 
bioavailability coupled with its extensive and rapid metabolism in the liver, 
resulting in a short elimination half-life (t1/2). However, co-administration with 
subtherapeutic doses of ritonavir improves these pharmacokinetic properties of 
lopinavir allowing the drug to exert its highly potent antiretroviral activity [175, 
176]. 
Mechanism of action of Protease inhibitors 
 Lopinavir is a higly potent inhibitor of HIV-1 protease [177, 178]. This 
enzyme is a homodimeric aspartic protease involved in the post-translational 
processing of viral gag and gag-pol polyprotein products into functional core 
proteins and viral enzymes [179]. HIV PIs, including lopinavir, prevent cleavage 
of gag and gag-pol protein precursors in acutely and chronically infected cells, 




HAART associated hepatotoxicity and liver injury 
 HAART causes a variety of adverse effects like cardiovascular diseases, 
neurological disorders, liver disease, lipodystrophy, non-Hodgkin lymphoma to 
name a few. Liver disease is recognized as an increasingly important problem for 
the HIV population, and may be due to a variety of factors including co-infection 
with viral hepatitis, alcohol abuse, and antiretroviral hepatotoxicity. Liver disease 
is now a leading cause of death for patients with HIV. In patients co-infected with 
HIV and hepatitis C, cirrhosis was the underlying cause of death in nearly 50% 
[171]. In a more general HIV population, liver disease was the second most 
common non-HIV-related cause of death, trailing only cancer [182]. The earlier 
retrospective study showed that the discontinuation of ART due to hepatotoxicity 
increased from 6% in 1996 to 31.8% in 1998-1999 and was the main cause of 
death in HIV infected individuals [183]. The severity of liver toxicity ranges from 
the absence of symptoms to liver decompensation, and the reported incidence of 
severe liver toxicity after initiating HAART ranges from 2% to 18%. Hepatotoxicity 
due to HAART is also common and up to 30% of patients on HAART experience 
World Health Organization grade 3 liver enzyme elevations. Hepatotoxicity 
induced by these agents has been identified on the basis of circulating liver 
enzymes (ALT, AST, and GGT) in association with increased lactate levels. In 
more dramatic situations, liver failure has occurred leading to discontinuation of 
treatment. The study of hepatotoxicity induced by HAART is complicated by the 
diverse chemical nature of the agents and by the differences between the effects 
of agents used singly or in combination. Hepatotoxicity from antiretroviral drugs 
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has led to adverse patient outcomes either from fulminant hepatic failure, or more 
commonly, AIDS following discontinuation of HAART. Mechanisms contributing 
to the adverse effects of HAART induced hepatotoxicity are still largely 
undetermined. Hence, it is highly relevant to study the underlying mechanisms of 
HAART-induced hepatotoxicity.  
Role of ER-stress in HIV-PI induced liver injury  
 Recent evidence suggests that HIV-PIs induce ER-stress and promote 
liver injury [184-186]. The ER is a critical organelle responsible for proper protein 
folding, cellular calcium levels, lipid synthesis and the secretory pathway. ER 
stress is primarily mediated by the ER protein BiP/GRP78 (Glucose regulated 
protein 78) via three ER sensors ATF6 (activating transcription factor 6), IRE-1 
(inositol-requiring enzyme1), and PERK (protein kinase RNA-like endoplasmic 
reticulum kinase). ER stress comprises both pathologic and adaptive responses; 
UPR adaptive responses reduce the protein burden by decreased synthesis and 
increased ER-associated degradation (ERAD) of proteins, and by inducing ER 
chaperones to enhance folding capacity. If the adaptive/protective reactions are 
inadequate or if the ER stress is prolonged/extreme, apoptotic cell death ensues 
via pathways involving activation of JNK (cJun N-terminal kinase) and caspase-
12, and upregulation of proapoptotic proteins like CHOP (CCAAT/enhancer-
binding protein homologous protein)[187]. CHOP also known as growth-arrest 
DNA damage-inducible gene 153 (GADD153) is a major transcription factor 
involved in ER-tress mediated apoptosis [188].  
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 HIV PIs, individually or in combination were shown to increase ER-stress 
markers such as active sterol regulatory element-binding proteins (SREBPs), X 
box binding protein 1 (Xbp1), activating transcription factor 4 (ATF-4), C/EBP 
homologous protein (CHOP) and caspase-12, leading to apoptosis in 
macrophages and rat hepatocyte. Additionally, ER calcium store depletion and 
lipid dysregulation in the ER by HIV PIs were shown to activate unfolded protein 
response in the hepatocytes [184, 185, 189].  Co-factors such as alcohol or 
Hepatitis C or B virus may exacerbate HIV-PIs induced ER-stress and liver injury.     
Role of Fas/FasL pathway in drug induced liver injury 
 Liver is an important organ for metabolism and elimination of foreign 
substances. Hence it is targeted for drug toxicity. Excessive hepatocyte cell 
death has been shown to be the central mechanism of liver damage in conditions 
such as viral hepatitis; alcoholic steatohepatitis, non-alcoholic steatohepatitis 
(ASH and NASH) as well as drug induced liver injury (DILI). The Fas/FasL 
signaling pathway has been implicated in various liver pathologies including 
Wilson’s disease, alcoholic liver disease (ALD), acute fulminant hepatitis, as well 
as chronic viral hepatitis [190-192]. Fas (CD95) is a death receptor in the tumor 
necrosis factor receptor (TNFR) family and is expressed in a variety of 
tissue[193]. Upon binding, the receptor undergoes trimerization and forms the 
intracellular death-inducing signaling complex (DISC) [193, 194]. This DISC 
include Fas-associated protein with death domain (FADD). This activates 
caspases signaling cascade via mitochondria dependent and independent 
pathways leading to apoptotic cell death [193]. Typically hepatocytes express 
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high levels of Fas receptor and respond to FasL signals from activated immune 
cells; however, under pathologic conditions such as alcoholic cirrhosis, 
hepatocytes also express high levels of FasL, leading to fratricide and liver injury. 
Moreover, endotoxin-induced liver injury in mice occurs via the Fas/FasL 
pathway following induction of Fas by IL-18 from Kupffer cells, and hepatocyte 
death induced in mice following exposure to anti-Fas antibody (JO-2) is an 
accepted model of fulminant hepatitis. With regards to HIV-positive individuals, 
increased expression of FasL is seen in cardiomyocytes, which contributes to 
AZT-Induced cardiomyopathy [195].  
Role of Phosphodiesterase 4 (PDE4)/cAMP in liver injury 
 cAMP is a second messenger that plays a critical role in regulating 
multiple cellular functions and its levels are tightly regulated through biosynthesis 
by adenyl cylases (ACs) and hydrolysis by phosphodiesterase (PDEs). cAMP 
exerts its effect through effector molecules protein kinase A (PKA) and  
Exchange Protein directly Activated by cAMP (EPAC), also known as cAMP-
GEF. There are 11 different members of the mammalian class I PDE super 
family, (PDE1-PDE11); within the families there are multiple genes and a large 
number of PDE splicing variants. Distinct kinetic and functional properties are 
attributed to PDE families with some specifically hydrolyzing cAMP, some both 
cAMP and cGMP, and others only cGMP [196, 197]. Of the cAMP specific PDEs, 
the PDE4 family is widely expressed and is the current therapeutic target for the 
treatment of inflammatory diseases, such as asthma and chronic obstructive 
pulmonary disease, as well as depression and cognitive deficit [197, 198].  
	95	
	
PDE4 accounts for the majority of cAMP hydrolysis activity in cells[199]. PDE4 
represents a large and complex family, with 4 genes (PDE4A/B/C/D) encoding 
over 20 distinct PDE4 isoforms as a consequence of distinct promoter usage and 
mRNA splicing; notably, these isoforms have similar catalytic activities but 
distinct cellular functions. PDE4 isoforms are regulated by transcriptional and 
post-translational mechanisms. Work done in our lab has shown that PDE4 
expression is significantly increased in response to alcohol exposure in 
monocytes/macrophages including hepatic Kupffer cells [200]. Notably, Work 
done by us and others has shown that regulation of cellular cAMP levels via 
degradation by phosphodiesterase (PDEs), particularly cAMP-specific 
 PDE4B plays an essential role in LPS-induced TLR4 signaling and 
inflammatory cytokine expression by monocytes/ macrophages [201-203](Jin and 
Conti, 2002; Jin et al., 2005; Gobejishvili et al., 2011). Additionally, in cholestatic 
liver injury, besides downregulating systemic and hepatic inflammatory cytokines, 
increases in cAMP have been shown to protect hepatocytes from apoptosis due 
to several related stimuli, including bile acids, LPS, Fas, and TNF-α [204-207]. 
 In another study done by our lab bile duct ligation mediated liver injury and 
apoptosis was significantly attenuated by PDE4 inhibition as assessed by 
reduced liver enzyme levels, decreased TUNEL staining, and PARP-1 cleavage. 
Hence, in addition to its anti-inflammatory effects, PDE4 inhibition, which leads to 
increased cellular cAMP levels, could also attenuate hepatocyte death. Indeed, 
cAMP has been shown to protect hepatocytes from bile acid–induced death by 
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We hypothesized that Protease inhibitor induced PDE4 expression and altered 
cAMP metabolism plays a major role in the induction of hepatocyte ER-stress, 
apoptotic gene expression and injury. (Fig. 30) 
 
 






SIGNIFICANCE & CLINICAL RELEVANCE 
 In the United States, approximately 2000 cases of acute liver failure occur 
annually and drugs account for over 50% of them (39% are due to 
acetaminophen, 13% are idiosyncratic reactions due to other medications). 
Drugs account for 2-5% of cases of patients hospitalized with jaundice and 
approximately 10% of all cases of acute hepatitis. HAART has been associated 
with increase in morbidity and mortality due to HAART-related hepatotoxicity and 
finally discontinuation of therapy. This is especially true in patients who are co-
infected or have other cofactors such as alcohol abuse. The mechanisms for 
HAART hepatotoxicity have received very limited attention. There is no well-
accepted therapeutic intervention except for abstinence and HAART 
discontinuation. Since liver is the first organ exposed and metabolized by the 
drugs it becomes highly relevant to understand the mechanism of drug toxicity. 
Findings from this project could provide important mechanisms by which HAART-
PI induced pathology causes cell death in hepatocyte often observed by 
prolonged drug intake in HAART medication. Moreover, the findings from this 
study would be significant in the development of successful preventive and 
therapeutic strategies in most-at-risk populations. Finally, the proposed studies 
will focus on direct hepatotoxicity due to HAART by the combinations of ritonavir 
and lopinavir (HAART PIs drugs), defining the disease mechanisms and 





MATERIALS AND METHODS 
Reagents 
PI drugs Ritonavir and Lopinavir were purchased from Selleckchem (Houston 
TX). Rolipram was purchased from Enzo Life sciences (Farmingdale, NY). H-89 
and Dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, 
MO). Horse serum was purchased from ATCC. Fetal bovine serum was 
purchased from Atlanta Biologicals (Norcross, GA). DMEM, penicillin, 
streptomycin and TRlzol® were obtained from Invitrogen (Carlsbad, CA). All RT-
PCR reagents were purchased from Applied Biosystems (Foster City, CA). MTT 
(Thiazolyl Blue Tetrazolium Bromide) was obtained from Sigma-Aldrich (St. 
Louis, MO). 
Cell Culture 
H4IIEC3 rat hepatoma cells (ATCC, Rockville, MO) were cultured in Dulbecco's 
modified eagle medium (DMEM) supplemented with 10% Horse Serum and 5% 
fetal bovine serum (FBS), 10 U/ml penicillin, and 10~g/ml streptomycin. Cells 
were maintained in an incubator at 37°C with humidified 5% CO2. Cells were 
plated and incubated overnight before treatment, in all experiments. 
Cell Survival Assay 
The MTT assay was used to assess cell survival. For the MTT assay, cells were 
plated in 96 well microplates, incubated overnight and treated with the treatments 
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mentioned in results for 24 hours. Treatments were then removed and MTT 
made in fresh DMEM (1 mg/ml) was added to the wells (100 µl/well). After 
incubation at 37°C with humidified 5% CO2 for 1-3 hours, DMSO (200 µl/well) 
was added. Cell viability was quantified colorimetrically by measuring 0.D. at 570 
nm.  
RNA Isolation and Real-Time PCR Analysis 
Total RNAs were isolated from liver tissue and cell cultures using TRIzol reagent 
(Invitrogen, Carlsbad, CA) and treated with DNase I to remove any contaminating 
genomic DNA (RQ1 RNase-Free DNase; Promega). For RT-qPCR, the first-
strand cDNA was synthesized using qScript cDNA SuperMix (Quanta 
Biosciences, Inc., Gaithersburg, MD). qRT-PCR was performed in triplicate with 
an ABI Prism 7500 sequence detection system and Perfecta SYBR Green 
FastMix, Low ROX reagents (Quanta Biosciences). The RT conditions were 10 
mins at 25°C, 30mins at 48°C and 5 mins at 85°C. Each sample was run in 
duplicate reactions. Reverse transcriptase polymerase chain reaction (RT-PCR) 
assays were used to assess mRNA levels of desired genes in liver tissues as 
well as hepatocytes H4IIEC3 cells. The primers amplifying the genes examined 
were designed in the lab and obtained from Intergrated DNA Technologies, Inc 
(Coralville, IA). The parameter threshold cycle (Ct) was defined as the fraction 
cycle number at which the fluorescence passed the threshold. The relative gene 
expression was analyzed using the 2-AACt method by normalizing with β-actin 
mRNA gene expression in all the experiments and is presented as fold change 
over Untreated which is set at 1. 
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Western Blot analysis 
Total cellular extracts were prepared by lysing the cells in RIPA lysis buffer 
(25mM Tris/HCL pH 7.5, 150mM NaCl, 1% NP-40, 0.1% SDS, 1mM DTT, 10% 
glycerol, 1x protease inhibitor cocktail, 0.5% sodium deoxycholate, 1mM Na2VO3 
and 10mM NaF). Protein samples were prepared in SDS loading buffer and 
proteins were separated by electrophoresis on 10% polyacrylamide gels and 
transferred onto a PVDF membrane. The blots were blocked with 5% (w/v) 
nonfat dry milk constituted in 1x TBS-T (Tris buffered saline, 10mM Tris HCL pH 
8.0, 150 mM NaCl, 0.1% Tween 20) for 1 hour at room temperature. Membranes 
were incubated at 4°C overnight with primary antibodies directed against protein-
of-interest in 5% (w/v) nonfat dry milk in 1x TBS-T. After overnight incubation in 
primary antibod, blots were washed and incubated with appropriate horseradish 
peroxidase-conjugated secondary antibodies for an hour. Immunoreactive bands 
were visualized using the enhanced chemiluminescence light (ECL) detection 
reagents (Amersham, Arlington Heights, IL). Data shown are representative of 2 
separate experiments showing similar results. Primary antibodies for AFT3, 4 
CHOP, PDE4A, B D and FasL were purchased from cell signaling. β-actin 
antibody was obtained from Sigma-Aldrich (St. Louis, MO). Secondary antibodies 
against mouse and rabbit were obtained from Santacruz Biotechnologies, Inc. 
(Santacruz, CA). 
 Statistical Analysis 
 Data are presented as means± SD for the indicated number of independently 
performed experiments. Student's t-test and one-way ANOVA with Bonferroni 
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multiple comparison test were used for the determination of statistical 
significance. P<0.05 was considered significant. 
 
 
mRNA PCR Primer Sequences 
	
primer name Sequence 
rATF3_F1 GGGCCACCTCAGACTTGGTGACT 
rATF3_R1 CATCGGATGTCCTCTGCGCTGG 
    
rATF4_F1 AAGCCATGGCGCTCTTCACGA 
rATF4_R1 AGTCCCCCGCCAACACTTCG 
    
rDDIT3_GADD_CHOP_F1 TGTTGAAGATGAGCGGGTGGCAG 
rDDIT3_GADD_CHOP_R1 TGGACCGGTTTCTCTCTCCTCAGGT 
    
r.n_FasL_F1 CTCTGGTTGGAATGGGGTTA 
r.n_FasL_R1 TTGGTTTCAGAGGGTGTGCT 
    
r.n._Fas_F2 CATTTTGCTGTCAACCGTGT 
r.n._Fas_R2 CGTGTACTCCTCCCCTTCTG 
    
rActb_F2 CAGCTGAGAGGGAAATCGTG 
rActb_R2 CTCCAGGGAGGAAGAGGATG 
    
rPde4acm1_F ATGGCTGAGTTCTTCCAGCA 
rPde4acm1_R CCATGTCTCCCACAATGGAT 
    
rPde4bcm2_F GGAGTTGTATCGGCAATGGA 
rPde4bcm2_R CAATGAAACCAACCTGGGACT 











In this study we investigated the mechanisms involved in HIV-PI induced 
hepatotoxicity. We specifically examined the role of ER-stress and apoptotic 
Fas/Fas expression in the HIV-PI mediated hepatocyte death. Importantly, we 
determined the pathogenic role of PDE4 /cAMP metabolism in the development 
of HIV-PI-induced hepatotoxicity. 
HIV-protease inhibitors induces PDE4 expression in H4IIE rat hepatoma cell 
line 
Work done by our research group has demonstrated that PDE4 expression 
leading to a decline in cellular cAMP levels plays a major pathogenic role in the 
development of alcohol induced liver disease and cholestasis liver injury and 
fibrosis [200, 209]. Hence we investigated the involvement of PDE4 enzymes in 
PI-induced hepatotoxicity. mRNA gene expression was carried out to profile the 
expression of PDE4 sub-families A,B and D in H4IIE hepatocytes treated with 
Ritanovir (Rit) and Lopinavir (Lop) (20µM) each singly and in combination. 
Differential pattern of the gene expression in PDE4 sub-family member was 
observed (Fig.31). Specifically, PDE4B gene expression was induced as early as 
3hrs by the combination treatment of Rit and Lop. PDE4B expression was 
observed to go back to baseline by 6 hours. In contrast PDE4A and PDE4D 
mRNA expression was only observed to be significantly induced by the PI 
combination at 24hrs in the combinatorial treatment of Ritanovir and Lopinavir 
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(20µM). Further, in correspondent to the changes in mRNA expression the 
combination of PI drugs showed an increase in PDE4B and PDE4D protein 
expression as shown by western blot analysis (Fig31); interestingly PDE4A 
protein expression did not show an appreciable change in the cells treated with 
PIs together at 24hours. Since western blot data was done only at 24hrs, 
possibility of PDE4A induction by PI drugs at early time-points or time-points after 
24hrs cannot be ruled out.  Overall this data suggests that PIs in combination 
induce PDE4 expression in hepatocytes that can affect cAMP metabolism.  
Inhibition of PDE4 led to a significant increase in the survival of HIV-PI 
treated H4IIE rat hepatocytes 
Cell viability was measured in hepatocytes treated with individual drugs 
(Ritanovir 20uM or Lopinavir 20uM) and combination (Ritanovir and Lopinavir 
20uM each) for 24hrs. The effect of PDE4 inhibition was examined by adding 
rolipram along with Rit+Lop combined treatment. Individual drugs Ritanovir and 
Lopinavir decreased cell viability by 30% whereas combination of drugs 
(R+L20uM) further significantly decreased it by 55% as compared to untreated 
(Fig.32).  However addition of rolipram along with (Rit+Lop) prevented the loss of 
hepatocyte and increased survival upto 65% (Fig.32). This data indicates that 
(Rit and Lop) singly and in combination induces cell death in hepatocytes 
whereas inhibition of PDE4 by the addition of rolipram significantly increased the 

























































































































































Fig. (31) HIV-PI drugs induce PDE4A, B and D mRNA and protein expression: 
H4IIE cells were exposed to Ritonavir (Rit)20µΜ and Lopinavir (Lop)20µΜ singly 
and in combination with or without Rolipram (Rol)10µM at the above mentioned 
time points. mRNA expression was examined by real-time PCR using primers 
specific for PDE4A, B and D. Data represented as the mean ± SE (n=5). 
Statistical analysis was performed using GraphPad Prism software using one-
way ANOVA followed by Bonferroni posttest. P<0.01. ‘a’ when compared to 
untreated (UT) ‘d’ when compared to Rit+Lop. Western blot analysis of PDE4A, B 
and D was performed using total cell lysates. GAPDH was probed to ensure 
equivalent protein loading. Densitometry analysis was performed using 
ImageLab software. Density ratio was calculated using β-actin as control. Blots 

















































Fig.(32) HIV-PI induced hepatocyte death is partially reversed by Rolipram: H4IIE 
cells were exposed to Ritonavir (Rit)20µΜ and Lopinavir (Lop)20µΜ singly and in 
combination with or without Rolipram (Rol)10µM in a 96 well format for 24hrs. 
Loss of hepatocyte survival was measured by MTT assay and plotted as a bar 
graph with 100% survival rate in UT cells. Data represented as the mean ± SE 
(n=4). Statistical analysis was performed using GraphPad Prism software using 
one-way ANOVA followed by Bonferroni posttest. P<0.01. ‘a’ when compared to 















HIV-PIs induced ER-Stress was significantly attenuated by PDE4 inhibition 
Previous studies have shown that HIV-PI induces ER-stress and unfolded protein 
response (UPR) and apoptosis in hepatocytes [185, 210]. Specifically, the 
combination of HIV-PI ritonavir and lopinavir significantly activated UPR in 
various hepatic cells; hence, we investigated the role of phosphodiesterase in 
HIV-PI induced ER-stress. Studies have also shown that CHOP knockout mice 
were protected from HIV-PI induced ER-stress, inflammation and hepatic 
lipotoxicity [211]. Prolonged translation of ATF4 and 3 was shown to be 
responsible for CHOP transcription [212]. We investigated the effect on ATF3, 4 
and CHOP as hallmark ER-stress proteins in HIV-PI treated cultured 
hepatocytes. H4IIEC3 cells were treated with Rit and Lop (20µM each) singly and 
in combination for a period of 6, 12 24 and 48hrs. Our results showed a 
sustained induction of ER-stress genes ATF3, ATF4 and CHOP from 6hrs to 
48hrs of PI drug exposure. Although, we did not report any significant increase of 
ER-stress genes by individual drugs, a trend was seen. Additionally this data was 
further confirmed by western blot analysis (Fig.33a,b,c,d). To address the causal 
role of PDE4 expression in the induction of ER-stress by PI drugs, PDE4 
specific/selective inhibitor Rolipram was used. Rolipram (10uM) treatment was 
shown to significantly down-regulate the induction of PI-induced ER-stress 
markers at gene as well as protein level for all the time-points. This data 
indicated that PDE4 expression induced by PI drugs is playing regulatory role in 





PIs induces Fas Receptor and FasL gene expression in hepatocytes 
Fas/Fas Ligand signaling is one of the most critical pathways involved in 
apoptosis induced cell death in hepatocytes[213]. Moreover, previous reports 
have shown the mechanistic link between proapoptotic ER-stress and the Fas 
and mitochondrial pathways of apoptosis via CamKII signaling [214]. CamKII 
signaling activates Fas receptor mediated apoptosis process in ER-stressed 
macrophages thus providing an unifying mechanistic link between UPR and 
apoptosis. Hence along with ER-stress expression we also investigated the role 
of Fas/FasL pathway in the PI-mediated apoptotic cell death in the hepatocytes. 
We did not report any significant up-regulation of FasL in Ritanovir and Lopinavir 
at 20µM treated individually. However, cells treated with the combination of 
Ritanovir and Lopinavir at 20µM significantly induced FasL gene expression at 
24hrs that was further up regulated at 48hrs. We did not get any significant 
induction of FasL gene expression at 6 and 12hrs suggesting that pro-apoptotic 
FasL signaling was occurring only at later time-points (data not shown). 
Moreover, Western blot analysis revealed that FasL protein expression was 
markedly increased in the combinatorial treatment of PI as compared to 
untreated in the hepatocytes. Similarly, Fas R was also significantly up-regulated 
by PI combinatorial treatment on the hepatocytes. Rolipram treatment 
significantly reversed this PI-drug induced up-regulation. This data showed for 
the first time that cAMP depletion/PDE4 inhibition could have an influence on 




PDE4 inhibition down-regulates FasL expression in the hepatocytes 
Previously, we have shown that PIs modulate PDE4/cAMP levels in the 
hepatocytes. Hence we wanted to investigate the role of PDE4/cAMP 
metabolism in regulating FasL gene expression. Rat hepatocytes were treated 
with Rit/Lop and rolipram. As expected, FasL gene expression as well as protein 
was completely abrogated by Rolipram (Fig.34). This data indicates that FasL 
plays a major role in PI induced cell death in hepatocytes and more importantly, 
PDE4 inhibition via rolipram significantly protected hepatocytes by down-
regulating FasL-induced cell death.  
Role of cAMP-PKA signaling in PI induced ER-stress and FasL mediated 
cell death in hepatocytes 
Previously, we have shown that ER-Stress as well as FasL-mediated cell death 
is regulated by PDE4 expression. In an assumption that the PI drugs 
compromised cellular cAMP levels we investigated the role of cAMP signaling in 
PI-induced upregulation of ER-stress and FasL expression. cAMP exerts its 
downstream effects by phosphorylating and activating its targets such as protein 
kinase A (PKA) and Exchange proteins activated by cAMP (EPAC). Hence to 
determine whether cAMP-PKA signaling is involved in PI-induced ER-stress in 
hepatocyte we examined the effects of a PKA inhibitor (H-89) (5uM) along with 
HIV-PI and rolipram. H4IIEC3 cells were treated with Rit +Lop with/without 
rolipram. As shown previously, rolipram treatment significantly down-regulated 
ER-stress genes ATF3, 4 and CHOP as well as FasL at 24hrs. Addition of H-89 
to rolipram and PI-treated cells significantly reversed the rolipram effect of ER-
stress and FasL suppression (Fig. 35). This data suggests that cAMP-PKA could 
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play a key role in regulating ER-stress and FasL mediated cell death in 
hepatocytes. We also speculate that PI drugs could be affecting PKA 















































































































































Fig. (33a) HIV-PI mediated ER-stress gene, ATF4 expression is down-regulated 
by PDE4 inhibitor, Rolipram: H4IIE cells were exposed to Ritonavir (Rit) 
20µΜ and Lopinavir (Lop) 20µΜ singly and in combination with or without 
Rolipram (Rol) 10µM at the above mentioned time points. mRNA expression was 
examined by real-time PCR using primers specific for ATF4. Data represented as 
the mean ± SE (n=5). Statistical analysis was performed using GraphPad Prism 
software using one-way ANOVA followed by Bonferroni posttest. P<0.01. ‘a’ 


































Fig. (33b) HIV-PI mediated ER-stress gene ATF3 expression is down-regulated 
by PDE4 inhibitor, Rolipram: H4IIE cells were exposed to Ritonavir 
(Rit)20µΜ and Lopinavir (Lop)20µΜ singly and in combination with or without 
Rolipram (Rol)10µM at the above mentioned time points. mRNA expression was 
examined by real-time PCR using primers specific for ATF3. Data represented as 
the mean ± SE (n=5). Statistical analysis was performed using GraphPad Prism 
software using one-way ANOVA followed by Bonferroni posttest. P<0.01. ‘a’ 













































































































































Fig. (33c) HIV-PI mediated ER-stress gene CHOP expression is down-regulated 
by PDE4 inhibitor, Rolipram: H4IIE cells were exposed to Ritonavir 
(Rit)20µΜ and Lopinavir (Lop)20µΜ singly and in combination with or without 
Rolipram (Rol)10µM at the above mentioned time points. mRNA expression was 
examined by real-time PCR using primers specific for CHOP. Data represented 
as the mean ± SE (n=5). Statistical analysis was performed using GraphPad 
Prism software using one-way ANOVA followed by Bonferroni posttest. P<0.01. 

















Fig. (33d) HIV-PI mediated ER-stress protein expression is significantly 
attenuated by PDE4 inhibitor, Rolipram: H4IIE cells were exposed to Ritonavir 
(Rit)20µΜ and Lopinavir (Lop)20µΜ singly and in combination with or without 
Rolipram (Rol)10µM at 24hrs. Western blot analysis of ATF3, ATF4 and CHOP 
was performed using total cell lysates. GAPDH was probed to ensure equivalent 
protein loading. Densitometry analysis was performed using ImageLab software. 
Density ratio was calculated using GAPDH as control. Blots are representative of 
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Fig (34) HIV-PI mediated Fas and FasL expression is down-regulated by PDE4 
inhibitor, Rolipram: H4IIE cells were exposed to Ritonavir (Rit)20µΜ and 
Lopinavir (Lop)20µΜ singly and in combination with or without Rolipram 
(Rol)10µM at the above mentioned time points. mRNA expression was examined 
by real-time PCR using primers specific for FasL and Fas.  Data represented as 
the mean ± SE (n=5). Statistical analysis was performed using GraphPad Prism 
software using one-way ANOVA followed by Bonferroni posttest. P<0.01. ‘a’ 
when compared to untreated (UT) ‘d’ when compared to Rit+Lop.  Western blot 
analysis of FasL was performed using total cell lysates. β -actin was probed to 
ensure equivalent protein loading. Densitometry analysis was performed using 
ImageLab software. Density ratio was calculated using GAPDH as control. Blots 























































































































































Fig (35) PKA inhibitor H-89 significantly reversed the protective effect of Rolipram 
on ER-stress and FasL gene expression: H4IIE cells were exposed to Ritonavir 
(Rit)20µΜ and Lopinavir (Lop)20µΜ singly and in combination with or without 
Rolipram (Rol)10µM along with PKA inhibitor H-89 (5µΜ) at 24hrs. mRNA 
expression was examined by real-time PCR using primers specific for ER stress 
gene ATF4,3, CHOP and FasL.  Data represented as the mean ± SE (n=5). 
Statistical analysis was performed using GraphPad Prism software using one-
way ANOVA followed by Bonferroni posttest. P<0.01. ‘a’ when compared to 
untreated (UT) ‘b’ when compared to Rit+Lop and ‘c’ when compared to 








	 HIV-protease inhibitors are used as combinatorial therapy and have 
significant therapeutic potential in the treatment of HIV-infection [215]. However, 
the prolong use of PIs has significant hepatotoxic effects [183].  Although, PI-
induced hepatotoxicity has been examined, the underlying mechanisms are not 
yet fully elucidated.  Previous studies have shown that PI-induced endoplasmic 
reticulum (ER) stress response play an important role in the development of 
inflammation, dyslipidemia, and insulin resistance [185, 216-219]. In the present 
work, molecular mechanisms driving PI-induced ER stress were investigated. 
Specifically, since combination of Rit and Lop constitutes a common PI-treatment 
regimen for HIV patients, their hepatotoxic effects were examined. The dose of 
Rit (20 μM) and Lop (20 μM) employed in the present studies was based on 
earlier clinical and experimental findings of anti-viral efficacy and hepatotoxicity 
[184, 185, 220-222].  As seen in earlier studies, our initial examination of the 
effect of Rit and Lop on hepatocytes showed that their combination was able to 
significantly induce ER stress. Particularly, expression of critical ER-Stress 
proteins such as ATF3, 4 and a known pro-apoptotic protein GADD153/CHOP 
were significantly up-regulated. To address the mechanisms underlying PI-
inducible ER stress we investigated the potential role of PDE4 expression that 
leads to a decline in cellular cAMP levels. The rationale for examining PDE4 
expression was provided by the earlier studies done by our research group [203]. 
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These studies have demonstrated the major pathogenic role of PDE4 expression 
and cAMP metabolism in experimental alcoholic liver disease and cholestatic 
liver inflammation, injury and fibrosis [203, 209, 223]. Additionally, work done by 
others has shown that increased cellular cAMP levels can effectively block 
hepatocyte apoptotic death induced by various stimuli including bile-acids, Fas 
and TNF [209, 223, 224]. Our data showed that Phosphodiesterase 4 (PDE4) 
plays a pathogenic role in PI-induced ER stress and apoptotic cell death in 
hepatocytes. Treatment of hepatocytes with the combination of Rit and Lop 
(Rit+Lop) differentially induced the expression of PDE4 subfamily members. 
Specifically, PDE4B mRNA expression was observed to be induced as early as 
3hrs post-treatment, whereas, there was a significantly delayed induction of 
PDE4A and D mRNA expression occurring at 24 h. Interestingly, examination of 
protein expression revealed only PDE4B and D subfamily members at 24 h. 
Since PDE4 members are the major cAMP-specific phosphodiesterase, their 
rapid and sustained induction by PIs potentially represents a pathogenic event 
decreasing hepatocyte cAMP levels and downstream signaling.   Since we 
observed an increase in the expression of both PDE4s and ER stress proteins in 
Rit+Lop treated hepatocytes, it is possible that PDE4 upregulation and ER-Stress 
are causally linked. The causal role of PDE4 was investigated by pre-treating the 
hepatocytes with Rolipram – a PDE4 specific inhibitor. Notably, PDE4 inhibition 
was able to abrogate Rit+Lop induced expression of ER stress genes and 
significantly enhanced hepatocyte survival. These data identify for the first time, 
PDE4 expression as the key mechanism that underlies PI-inducible ER stress 
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and hepatotoxicity.  With regards to ER stress mediated cell death, the induction 
of pro-apoptotic GADD153/CHOP is well correlated with the onset of ER stress-
associated apoptosis and has been observed to be induced by Rit+Lop in 
hepatocytes [225-227]. However, besides induction of GADD153/CHOP, ER 
stress has also been linked to Fas and mitochondrial apoptosis pathways [214]. 
Importantly, Fas-FasL mediated hepatocyte death has been demonstrated to 
contribute to drug induced hepatocyte cytotoxicity [228, 229]. Also, in relevance 
to this study, it has been demonstrated that cAMP inhibits FasL expression and 
apoptotic cell death in lymphocytes [230]. Since we identified that Rit+Lop 
significantly induces cAMP degrading PDE4 expression that is causally linked 
with the development of ER stress, we further examined the effect on Fas and 
FasL expression. The data obtained showed for the first time that Rit+Lop can 
significantly induce the expression of both Fas and FasL that are known to 
induce apoptosis and hepatocyte death. Notably, PDE4 expression was also 
determined to play a causal role in the Rit+Lop-inducible Fas and FasL 
expression. Inhibition of PDE4 leads to increased cellular levels of cAMP and a 
major component of the cellular effects of cAMP are mediated by cAMP 
dependent PKA (cAMP-PKA) activation and signaling [231].  Accordingly, our 
data suggested that the inhibitory effect of PDE4 inhibition decreasing ER stress, 
Fas and FasL expression could be mediated via cAMP-PKA activation. This 
aspect was evaluated by examining the effect of cAMP-PKA inhibitor on 
hepatocytes that were treated with Rit+Lop and Rolipram. The data obtained 
strongly suggests that cAMP-PKA activity is essential for the prevention of ER 
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stress, Fas and FasL expression and hepatotoxicity induced by combinatorial PI 
(Rit+Lop) treatment. Taken together, these data demonstrate that PDE4 
expression and consequent decrease in cAMP-PKA activation/signaling, plays a 
key pathogenic role in the induction of Rit+Lop hepatotoxicity by both individually 
or coordinately activating ER stress and Fas/FasL expression.  Significantly, 
these data also suggest that targeting PDE4 activity has therapeutic potential in 






SUMMARY AND CONCLUSIONS 
In the present study we investigated the role of Phosphodiesterase 4 
(PDE4) and ER-Stress as significant pathogenic mechanism in Highly Active 
Anti-retroviral Therapy (HAART) Induced Hepatotoxicity. The main purpose of 
HAART is to significantly improve the quality of life by suppressing the viral load 
and its replication in the body of an HIV (Human Immunodeficiency Virus) 
infected individual. This is achieved by administering multiple drug therapy used 
in HAART.  Protease Inhibitors (PIs) are being used as one of the therapies in 
the initial treatment of HIV infection. Even though these drugs have a positive 
impact on the patients, they are associated with several undesirable 
consequences in their long-term treatment. Some of the major complications of 
HAART are hepatotoxicity and lipodystrophy leading to its discontinuation.  
Hence it becomes highly relevant to investigate the mechanisms involved in PI 
induced hepatotoxicity. Recent studies have shown the involvement of ER stress 
and subsequent activation of the unfolded protein response (UPR) resulting in 
apoptosis/hepatocyte death as one of the cellular mechanisms of HIV-PI induced 
metabolic disorders.  
Additionally, cAMP is a known anti-apoptotic or a pro-survival signal in 
many different cell types including hepatocytes.  Specifically in hepatocytes, 
cAMP is involved in the protective mechanism from various insults such as Fas 
Ligand, TNF-α, and hydrophobic bile acids.  Our recent work shows that 
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PDE4/cAMP metabolism plays a significant role in alcohol-induced hepatic 
steatosis and injury. Phosphodiesterase (PDEs), a family of enzymes precisely 
regulates intracellular levels of cAMP via adenylyl cyclase are involved in their 
synthesis as well as degradation. Our recent work shows that PDE4/cAMP 
metabolism plays a significant role in alcohol-induced hepatic steatosis and 
injury. Hence in the present study, we examined the mechanisms underlying 
HIV-PI induced hepatic ER stress and toxicity with a particular emphasis on 
PDE4 family of enzymes.  
The effects of clinically used HIV-PIs (Ritonavir and Lopinavir) were 
examined both in a rat hepatoma cell line as well as rat primary hepatocytes. 
These studies demonstrated that PIs led to a significant loss of hepatocyte 
survival. Notably, inhibition of PDE4 by a specific PDE4-inhibitor, rolipram, 
markedly attenuated hepatotoxicity induced by PIs. Mechanistic role of PDE4 
showed that PDE4 inhibition significantly decreases the expression of the ER 
stress related proteins C/EBP homologous protein (CHOP), Activating 
transcription factor (ATF-4 and -3) induced by PIs. Furthermore, examination of 
the PDE4/cAMP-regulated downstream signaling demonstrated the involvement 
of PKA. Specifically, cAMP-PKA inhibitor H-89 reversed the rolipram effect of 
down-regulating the expression of the PI-induced ER-stress genes. These data 
identify an important pathogenic/mechanistic role for PDE4 regulated cAMP-PKA 
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